990-PF

Return of Private Fundation Exempt from Income Tax

1980

Hernel Mevenue Service		501(c)(3) of the In	AND THE PERSON NAMED AND POST OF THE PERSON N	A STATE OF THE PARTY OF THE PAR	- 10
	1980, or tax year beginning		1980 and endin	Employer identification	, 19
Please type,	me of organization YJ 36_6125258 990PF KROC FOUNDATION	12 4	04 03	36 61252	58
	dr N G A MOFFMAN		ģ.	if the foundation is month termination u	nder sec-
See Specific Cit	- SAN DIEGO V 8739 VILLA LA JOLLA DRI	CA Suite de	}+5+0+	tion 507(b)(1)(B) che Fair market value of	
	Ly Josep Cy 94017			year	
address changed, c		eign organizations,			
	FORD HICKMAN GIARS & MASS			If exemption application	on is pend.
ATT DESCRIPTION OF THE PARTY OF	is of Revenue and Expenses	(A) Revenue and	(B) Computation of	(C) Computation of	(D) Disbursement for exempt
	structions for Part I)	expenses per books	net investment income	adjusted net income	purpose
1 Gross contribut	ions, gifts, grants, etc. (see instructions)	50000			
	om split-interest trusts (see instructions) .				
3 Gross dues a	and assessments		Managari Sangari Sangar		
4 Interest .		361000	361000	361000	
5 Dividends .		1016 411	1016 411	1016 7 11	
6 Gross rents	and royalties		Minimum		
7 Net gain or (los	s) from sale of assets not on line 11				
Capital gain	net income (see instructions)				
The second of the second	m capital gain (see instructions)				
	ifications (see instructions)	<i>Managaman</i>	*************	•••••	
	from any business activities:	1			
(Gross receip	ots > \$ minus cost				
	(steppes)	217 709	43 ≠ 6 7 7	234677	
12 Other income	e (attach schedule (CE. 32" H	742 495	145,2263	1412-11	
1 34 Company	n of officers are instructions)	- CE (2 0 0 0	/4 4 9 9	/2400	4.76.
15 Other selecte	plan contribution (enter purchase)	MICE - + 4 - 83	488.7	##8.7	, 9 5 2 6
15 (a) Pension	plan contribution Senter purification	1			
au (a) rension	brau commonion (cure files	1			
(b) Other on	nployee benefits RNA RESTO	10107	2161	2161	8646
	legal, and other professional services	55571	41684	41684	13877
18 Interest	egal, and open professional services	***************************************			***************
19 Taxes (see in	nstructions)	304213	25,0	25.0	301700
District Annalysis of the Control of	mortization, and depletion (see instructions)	9052	-	9.52	
21 Rent					
4	ses (attach schedule) Sew.4 .	1562776	10012	10012	155296
The state of the s	, gifts, grants (see instructions)	+717.16	Mariana mariana da la companya da l	Madallin Sintilli.	471701
	nes 14 through 23	7.35795	117514	146636	67.715
5 (a) Excess of revenu	e over expenses: Line 13 minus line 24	(4 2 9 3 3 · ·)	Husensonstilled	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	******
	nt income (if negative enter ·O·)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	/ 4 8 9 4 C 7 9	Millian million	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	ome (see instructions) (if negative enter -0-)			1415452	Maddilladdani
STATE OF STREET STATE OF STREET	Tax On Investment Income				
_	ations enter 2% of line 25(b). Foreig	750	er 4% of line 25(b)		21717
was a second to the second to	ign organizations—tax withheld at so				
	paid with application for extension of				
	minus line 2. Pay in full with return. I		by order payable to	Internal Revenue	21719
	ployer identification number on chack	or money order) .			
Overpayment—lin	_	and fair market value			nt assets held in
reign organization—Ent	er book value > 3		adults and statements, a	nd to the best of my hos-	riodge and, beligh
true, correct,	Opligation of frishard (after then tangers)	tour on all interrupted		The second second	5/5/8
X MAG	MAN MICE		usul / n	marin	
Signature of offi	cer or trustee	Pote Frage	Microsian Gi	45 + Massing + 2	Accounted
Meso	5/1	1/8/	Micronan Gi	AS A MASSIME CA.	

Belence Sheets	Daginning	of tox year	End of	New year
Acces	(A) Amount	(B) Total	(C) Amount	(D) Total
1 Cook:	The state of the s			
(a) Savings and interest-bearing accounts	47,42		12/00	
(h) com	27671	76 113	26729	107029
2 Assemble resolvable and				
3 Notes receivable not (attach schedule)				
4 Immateries		***************************************		
S Covernment obligations:		***************************************		
(a) U.S. and instrumentalities			1723.11	
(b) State, subdivisions of States			•••••	1723018
6 Investments in corporate bands, etc. (attach schodule).		·•••		3521115
7 Investments in corporate stacks (attach schodule) Sen ?		50177497		37169740
8 Mortgage loons (number of loons >)				
9 Other Investments (attach schedule)	l	1966195		3077269
30 Depresiable (deplotable) assets (attach schedule):				
(n) Hold for investment purposes				
Co Man assumulated depresiation				
(t) Hold for charitable purposes Sev. 5 .	86795	***************************************	11771	
(d) Minus accumulated depreciation	3632.	5. 475	45372	#3 # 2 4
11 Lant:		***************************************		
(a) Hold for investment purposes				
(b) Hold for charitable purposes		***************************************		
22 Other assets (attach sendale) Scr. 3.	ł	153551		14065
12 Table annie		52 4452 38		46364742
I labillia				V CHARLES MONTH CONTROL OF THE PROPERTY AND ADMINISTRATION OF THE PROPERTY ADMINISTRATION OF THE PROPERTY AND ADMINISTRAT
14 (26384		59734
15 Contributions eithe process assemble	'			
26 Martenage and pales severble (attach achedule)		***************************************		
17 Other Habilities (attack schedule) Sch		109826		290280
SR Total Makilling		136210		347 - 14
Not Worth (Fund Belences)	l			El Disentacionales de la constante de la const
19 Principal food by				
***************************************		70 6:9359		69694534
Share and b		***************************************		
***************************************		<113.0851>		<236781.67
21 Total not worth (fund belances)		523-9-21		46015721
22 Total liabilities and not worth (line 18 plus line 21)		52445211		46364742
Analysis of Changes in Net Worth				
1 Total net worth at beginning of year-Part III,	Column B. line 21			523.9.25
2 Enter amount from Part I, line 25(a)				< 6 49 3 3 0 o
3 Other increases not included in line 2 (itemize)				
da commenda anno de describir de la companya del companya de la companya del companya de la comp			••••••	
	•••••••			
	••••••	•••••		
***************************************		·····		1
•••••••••••••••••••••••••••••••••••••••	•••••			
***************************************		••••••		
4 Total of lines 1, 2, and 3				46015721
5 Decreases not included in line 2 (iter ize)		***************************************		1
***************************************		••••••		1
***************************************		••••••	***************************************	1
***************************************			*******	1

6 Total net worth at end of year (line 4 minus line	5)—Part III, Column	D, line 21		46015728

	1 - 1	Statements Regarding Activities		
m	fore	4729 If you answer "No" to question 10(b), 11(b), or 14(b); or if you answer "Yes," to question 10(c), 12(b), 13(a), or 13(b).	Yes	No
		During the tax year, did you attempt to influence any national, State, or local legislation?		~
		During the year did you participate or intervene in any political campaign?		~
		Did you spend more than \$100 during the year (either directly or indirectly) for political purposes (see instructions for definition)?	7777777	V
		If you answered "Yes" to 1(a), (b), or (c), attach a detailed description of the activities and copies of any materials published or distributed by the organization in connection with the activities.		
	-		200000	
	Acres .	Did you file Form 1120-POL?		~
-	400 000	Yes," attach a detailed description of the activities.		West II
3	1200	19 you made any changes, not previously reported to the IRS, in your governing instrument, articles of incorpo-		
-		on, or bylaws, or other similar instruments?	Millian	en a cioni
	22 -	Yes," attach a conformed copy of the changes.	2116	1/22 12
. 4			WINNIN.	www.
		Did you have unrelated business gross income of \$1,000 or more during the year?		
	15,115	If "Yes," have you filed a tax return on Form 990—T for this year?		~
•	othe	Nere a liquidation, termination, dissolution, or substantial contraction during the year?		
•	-	Did you have at least \$5,000 in assets at any time during the year?		
_	-	If "Yes," did you file the annual report required by section 6056 (see Form 990–AR for instructions)?	<u> </u>	
7	Are	the requirements of section 508(e) (relating to governing instruments) satisfied? (See instructions)		
	-	Yes," are the requirements satisfied by:	_v	
	120	Language in the governing instrument (original or as amended), or		
	(b)	Enactment of State legislation that effectively amends the governing instrument with no mandatory directions		
_		in the governing instrument that conflict with the State law?	200000	VIVIAN
•	(e)	Enter States to which the foundation reports or with which it is registered (see instructions)		
	****	CALIFORNIA AND ILLINOIS		
		If you answered 6(a) "Yes," have you furnished a copy of Form 990-AR (or equivalent report) to the Attorney	Million.	
		General (or his/her designate) of each State as required by General Instruction K.1?		VIII (ICHO)
•	dar W	you claiming status as an operating foundation within the meaning of sections 4942(j)(3) or 4942(j)(6) for calen- year 1980 or fiscal year beginning in 1980 (see instructions for Part XII)?		
30		dealing (section 4941); During the year did you (either directly or indirectly);		
		(1) Engage in the sale or exchange or leasing of property with a disqualified person?		V
		(2) Borrow money from, lend money to, or otherwise extend credit to (or accept it from) a disqualified person?		~
		(3) Furnish goods, services, or facilities to (or accept them from) a disqualified person?		~
		(4) Pay compensation to or pay or reimburse the expenses of a disqualified person?		~
		(5) Transfer any of your income or assets to a disqualified person (or make any of either available for the		
		benefit or use of a disqualified person)?		-
	(b)	If you answered "Yes" to any of the questions 10(a)(1) through (6), were the acts you engaged in excepted acts		
		as described in the instructions for this line?		
	(c)	Did you engage in a prior year in any of the acts described in 10(a), other than excepted acts, that were acts of		
		self-dealing that were not corrected by the first day of your tax year beginning in 1980?		~
11	Tax	es on failure to distribute income (section 4942) (does not apply for years you were an operating foundation as		
		ned in section 4942(j)(3) or 4942(j)(6)):		
	(a)	Did you at the end of tax year 1980 have any undistributed income (lines 6(b) and (c), Part XI) for tax year(s)		
		beginning before 1980?		~
		If "Yes," list the years		
	(p)	If "Yes," to (a) above, are you applying the provisions of section 4942(a)(2) (relating to incorrect valuation		
		of assets) to the undistributed income for ALL such years?		777722
	(c)	If the provisions of section 4942(a)(2) are being applied to ANY of the years listed in (a) above, list the years		
		here and see the instructions >,		
12		es on excess business holdings (section 4943):		/
		Did you hold more than 2% direct or indirect interest in any business enterprise at any time during the year? If "Yes," did you have excess business holdings in 1980 as a result of any purchase by you or disqualified per-		
	(4)	sons after May 26, 1969; after the lapse of the 5-year period to dispose of holdings acquired by gift or bequest;		
		or after the lapse of the 10-year first phase holding period?		91. 411

	1000	mode.	23
- A -			-23

Part V Statements Regarding Activities (continue				
13 Taxes on investments which jeopardize charitable purpose (a) Did you invest during the year any amount in a man exempt purposes?	(section 4944): ner that would jeopar	dize the carrying	out of any of you	". Yes No
(b) Did you make any investment in a prior year (but after				• -
purpose that you had not removed from jeopardy on t	he first day of your ta	x year beginning	in 1980?	
14 Taxus on taxable expenditures (section 4945):(a) During the year did you pay, or incur any amount to:	,			
(1) Carry on propaganda, or otherwise attempt to of the general public or any segment thereof, or legislative body, or by communicating with any or in the formulation of legislation?	influence legislation or by communicating	with any member	er or employee of	
(2) Influence the outcome of any specific public e	election, or to carry	on, directly or i	ndirectly, any vot	*
registration drive?	or other similar purpor			
(4) Provide a grant to an organization, other than a	charitable, etc., orga	nization describ	ed in paragraph (1).
(2), or (3) of section 509(a)?				•
(5) Provide for any purpose other than religious, cha		erary, or education	mal purposes, or f	or v
the prevention of cruelty to children or animals?				•
(b) If you answered "Yes" to any of questions (a)(1) thr	rough (a)(5), were all	such transaction	ns excepted transa	C-
tions as described in the instructions?				a Should control of the second
(c) If you answered "Yes" to question 14(a)(4), do you openditure responsibility for the grant (as explained in	claim exemption from item (12) of the instr	uctions for line 1	4)? · · · · //	
If "Yes" attach the statement required.			~/	
Pact VI Statement Regarding Contributors, Comp				
1 Persons who became substantial contributors in 1980 (if	more space is needed	d, attach schedul Addr		
Name	8939 Ying 6		ve. Juice de	3
RAY A KROC	LA JOLLA CA	94437		•
144 4 1400				
The state of the s	r compensation if an	v for 1990:		
2 Officers, directors, trustees, foundation managers and their	Title, and time	Contributions	Expense ec-	
Name and address	devoted to position	to employee benefit plans	count, other allowences	Compensation
SCHEQUIE 5				
•••••			1	
	1			
Total				59655
3 Compensation of five highest paid employees for 1980 (other than included	in 2 above—see	instructions):	
Name and address of employees paid more than \$30,000	Title, and time devoted to position	Contributions to employee benefit plans	Expense ac- count, other allowances	Compensation
M Perez AMAGNER : 401 MOUNTAIN	CONFERENCE PASSA	,		2-99,
DRIVE SANTA BARBARA CA 98103	FULL TILLE	/994	<i>~•~€</i>	37881
WALTER F. GARRY 51. MONGREN	GARNI &	435.	None	39150
DRIVE, JANIA YNEE CA 9346.	FULL TIME			
	1			
Total number of other employees				
paid over \$30,000 ▶ ~ ~ €		mmannanimm	manaman and a second	man and the state of the state

Minimum Investment Return for 1980 (Operating Foundations—See instructions)

(Operating Foundations—see instructions)	
Pair market value of assets not used (or held for use) directly in carrying out exempt purposes:	
(a) Average monthly fair market value of securities	47 518 93
(b) Average of monthly cash belences	323910
(c) Fair market value of all other assets (see instructions)	57490
(d) Total (add lines (a), (b), and (c))	471954.3
R Acquisition indebtedness applicable to line 1 assets	
Line 1(d) minus line 2	47895403
6 Cash deemed held for charitable activities—enter 1½% of line 3 (for greater amount, see instructions)	
B Line 3 minus line 4	
	23528 + 9
S Enter 5% of line 5	
(See instructions—not applicable to operating foundations)	
Adjusted net income from Part I, line 25(c)	1413452
Minimum investment return from Part VIII, line 6	2357749
Enter the larger of line 1 or line 2	
Total of:	
(a) Tax on investment income for 1980 from Part II, line 1	
	27719.
(b) Income tax on unrelated business income for 1980 (Form 990-T)	
B Distributable amount (line 3 minus line 4)	2070953
6 Adjustments to distributable amount (see instructions)	
7 Distributable amount as adjusted (line 5 plus or minus line 6)—also enter in Part XI, line 1	2.70955
Qualifying Distributions in 1980 (See instructions)	
Amounts paid (including administrative expenses) to accomplish charitable purposes:	
(a) Expenses, contributions, gifts, etc.—total from Part I, column (D), line 24	69.915
(b) Program-related investments (see instructions)	
2 Amounts paid to acquire assets used (or held for use) directly in carrying out charitable, etc., purposes	
3 Amounts set aside for specific projects which are for charitable purposes	
4 Total qualifying distributions made in 1980 (add lines 1, 2, and 3)—also enter in Part XI, line 4	4909159

Computation of Undistributed Income (See instructions)	(a) Corpus	(b) Years prior to 1979	(c) 1979	(d) 1980
1 Distributable amount for 1980 from Part IX	in collection day	a martidade de 18	Subject to dear wife	2070755
2 Undistributed income, if any, as of the end of 1979:	CONTRACTOR	Million Server		A STATE OF THE STA
(a) Enter remount for 1979				CONTRACTOR CONTRACTOR
(b) Total for prior years:	NACHAMATA NASA	•	1988 Sept.	
3 Excess distributions carryover, if any, to 1980:			approximation	1000000
(a) From 1975	-			N. 10 N.
(b) From 1976	- haranan			
(c) From 1977	Maria			
(d) From 1978	-			
(e) From 1979	9033 33000			Secretary of the second
(f) Total of 3(a) through (e)	11977261	MANASA		A Samuel Sills
4 Qualifying distributions for 1980 (47-7/ 57				Maria Miller
(a) Applied to 1979, but not more than line 2(a) .			(–)	Commence of the second
(b) Applied to undistributed income of prior years			100000 to 100000000000000000000000000000	
(Election required)	100 May 11 11 11 11 11 11 11 11 11 11 11 11 11	(-)		SECTION AND YOU
(c) Treated as distributions out of corpus (Election required)				
(d) Applied to 1980 distributable amount	The second second			(2070955
(e) Remaining amount distributed out of corp is .	¥1311.4			Maria Maria Maria
5 Excess distributions carryover applied to 1980	(-)			www.manananana
(If an amount appears in column (d), the same				
amount must be shown in column (a))	Manager Committee			
6 Enter the net total of each column as indicated				
below:	16.8. 35.5 Mill. 18.00.00	1936/1904/14/14/14/14/14/14/14/14/14/14/14/14/14	(/////////////////////////////////////	
(a) Corpus. Add lines 3(f), 4(c), and 4(e). Subtract line 5	. 13:5474.			
(b) Prior years undistributed income. Line 2(b)				
minus line 4(b). This amount is taxable—File Form 4720		_		<u> </u>
(c) Undistributed it come for 1979. Line 2(a) minus line 4(a). This amount is taxable—File Form			-	
(d) Undistributed income for 1980. Line 1 minus				
lines 4(d) and 5. This amount must be dis- tributed in 1981				
${\bf P}$ Amounts treated as distributions out of corpus to				
satisfy requirements imposed by sections 170(b)	1 /			
(1)(D) or 4942(g)(3) (see instructions)				
8 Excess distributions carryover from 1975 not ap-	(270/0/)			
plied on line 5 or line 7 (see instructions)		2018/0.200000000000000000000000000000000000	West Statement	1000
9 Excess distributions carryover to 1981. (Line 6(a)	17925271			200000000000000000000000000000000000000
minus lines 7 and 8.)				
10 Analysis of line 9: (a) Excess from 1976				
(b) Excess from 1977				
(c) Excess from 1978	-			
(d) Excess from 1979				
(e) Excess from 1980 47 31 2 4			Mary Mary State St	

	Private Operating Founda (See instructions and Par		4/4			
) If the foundation has received a rulir tion, and the ruling is effective for :) Check box to indicate whether you	1980. enter the da	te of the ruling .		4942(j)(3) or [] 4942(j)(6) (see
	instructions).			Prior Three Years		-
	Adjusted not income ffrom Bart I	Ten yeer (a) 1980	(b) 1979	(c) 1978	(d) 1977	(e) Total
2 Q	Majusted net income (from Part I, line 25(c) for 1980. Enter corresponding amount for prior years)					
	Qualifying distributions from Part X, line 4 for 1980 (enter corre- appnding amount for prior years).				errore sources and annual sources are a	i
	Amounts included in (c) not used directly for active conduct of exempt activities					
	Qualifying distributions made di- rectly for active conduct of exempt purposes (line (c) minus line (d)).					
(b) rel	mplete the alternative test in (a), or (c) on which the organization les:					
	"Assets" alternative test—enter: (1) Value of all assets					
	(2) Value of assets qualifying under section 4942(j)(3)(B)(i)					-
(0)	"Endowment" alternative test— Enter 3/2 of minimum investment return shown in Part VIII, line 6 for 1980 (enter 3/2 of comparable amount for prior years)					
(e)	"Support" alternative test—enter: (1) Total support other than gross investment income (interest, dividends, rents, payments on securities loans					
	(section 512(a)(5)), or royal- ties)					
	zations as provided in section 4942(j)(3)(B)(iii)					
	(3) Largest amount of support from an exempt organization (see instructions)				*	
	(4) Gross investment income					

Schedule 1 - 12/31/80

Principal Investigator		
and Institution	Title of Project	Amount
Donald M. Marcus, M.D. Albert Einstein College of Medicine Bronx, NY	Glycosphingolipid antigens of human lymphocyte subpopulations	\$ 19,746
Kevin J. Lafferty, Ph.D. The Australian National University Australia	Human islet transplantation .	16,686
Helen V. Bashir, MB, BS, FRCPA John P. Edmonds, MB, BS, FRACP Andrew F. Geczy, Ph.D., D.Sc. Australian Red Cross Society Australia	Role of environmental agents in the pathogenesis of the seronegative arthropathies: a biochemical study	16,500
Lawrence Chan, M.D. Baylor College of Medicine Houston, TX	Biochemical studies on somatostatin biosynthesis	32,105
Donald M. Marcus, M.D. Baylor College of Medicine Houston, TX	Glycosphingolipid antigens of human lymphocyte subpopulations	23,464
W. Page Faulk, M.D. Blond McIndoe Centre for Transplantation Biology England	Immunological studies of diabetic placenta	27,175
John I. Loewenstein, M.D. Boston University Medical Center Boston, MA	Ocular blood flow in diabetes mellitus	7,065
Neil B. Ruderman, M.D., Ph.D. Boston University School of Medicine (University Hospital) Boston, Ma	Polyamine metabolism in diabetes	31,775
Michael P. Czech, M.D. Brown University Providence, RI	Chemistry of the insulin receptor	38,836
Jeremy P. Brockes, Ph.D. California Institute of Technology Pasadena, CA	A pituitary growth factor for cultured rat Schwann cells	39,770

Principal Investigator and Institution	Title of Project	_Aucunt
Alan G. Goodridge, Ph.D. Case Western Reserve University Cleveland, OH	Hormone action in mutant hepatocytes	\$ 22,601
Richard W. Hanson, Ph.D. Case Western Reserve University Cleveland, OH	Role of insulin in the regulation of enzyme synthesis	19,490
Irving Kushner, M.D. Case Western Reserve University Cleveland, OH	Regulation of biosynthesis of murine amyloid-associated proteins	6,462
Charles J. Malemud, Ph.D. Roland W. Moskowitz, M.D. Victor M. Goldberg, M.D. Case Western Reserve University Cleveland, OH	Studies of human cartilage growth and metabolism in aging and osteoarthritis	16,566
Harvey C. Gonick, M.D. Cedars-Sinai Medical Center Los Angeles, CA	Role of chromium deficiency as a cause of diabetes	39,400
James R. Klinenberg, M.D. Cedars-Sinai Medical Center Los Angeles, CA	A double blind controlled study of therapeutic lymphoplasm-pheresis in rheumatoid arthritis	14,774
John J. Miller, III, M.D., Ph.D. Children's Hospital at Stanford Palo Alto, CA	Role of antigen-antibody complexes in juvenile rheumatoid arthritis	27,617
Howard L. Weiner, M.D. Children's Hospital Medical Center Boston, MA	Natural killer cell activity in patients with multiple sclerosis and the relationship between human natural killer cells and measles virus	17,738
Jack R. Battisto, Ph.D. Cleveland Clinic Foundation Cleveland, OH	Studies on the altered IgG human rheumatoid arthritis and development of a mouse model for adjuvant arthritis	36,960
Randall S. Krakauer, M.D. Cleveland Clinic Foundation Cleveland, OH	Investigation in suppressor cells and adaptive immunotherapy in autoimmunity	32,721
Peter C. Dowling, M.D. Stuart Cook, M.D. College of Medicine and	Lyme agent associated joint and nervous system disease on Cuttyhunk Island	11,000
Dentistry of New Jersey		

Newark, NJ

Principal Investigator and Institution	Title of Project	Amount
John W. Prineas, M.D. College of Medicine and Dentistry of New Jersey Newark, NJ	Characterization of virus-like particles and demyelination in acute lesion in multiple sclerosis	\$ -0-
William V. Lumb, D.V.M., Ph.D. Colorado State University Fort Collins, CO	Kinetic analysis of cholesterol and bile acid metabolism after portacaval shunt in Yucatan swine	11,000
Eugene L. Pautler, Ph.D. Colorado State University Fort Collins, CO	Transport of glucose and amino acids across the blood-retinal barrier in streptozotocin-induced diabetic rats	7,986
Eugene L. Pautler, Ph.D. Colorado State University Fort Collins, CO	Glucose and amino acid transport in ocular tissues of dystrophic and diabetic rats	-0-
Robert W. Phillips, D.V.M., Ph.D. Colorado State University Fort Collins, CO	Yucatan miniature swine as a model for diabetes mellitus	100,148
Isidore Edelman, M.D. Columbia University College of Physicians and Surgeons New York, NY	Use of glucocorticoid analogs to characterize glucocorticoid receptors	34,090
Max J. Appel, D.V.M., Ph.D. James A. Baker Institute for Animal Health New York State College of Veterinary Medicine Cornell University Ithaca, NY	Canine viruses and multiple sclerosis	9,804
George Lust, Ph.D. James A. Baker Institute for Animal Health New York State College of Veterinary Medicine Cornell University Ithaca, NY	Canine hip dysplasia: a model for study of early events in osteoarthritis	39,617
Dolph O. Adams, M.D., Ph.D. Duke University Medical Center Durham, NC	Cytolytic proteases from mononuclear phagocytes in rheumatoid arthritis: effects on connective tissue cells and their regulation	12,530
Sergio L. Abreu, Ph.D. Fordham University Lronx, NY	Effects of interferon on experimental allergic encephalomyelitis and adjuvant arthritis	7,953

Principal Investigator and Institution	Title of Project	Amount
G. D. Aurbach, M.D. Edward M. Brown, M.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Electrical potential of parathyroid cells in response to secretagogues and extracellular calcium	\$ 3,256
Samuel W. Cushman, Ph.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Mechanism of insulin's stimulatory action on glucose transport in the isolated adipose cell	7,980
Monique E. Dubois-Daloq, M.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Culturing of large quantities of rat Schwann cells and study of their ability to myelinate or remyelinate axons in the central and peripheral nervous system	13,005
C. Ronald Kahn, M.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Study of the metabolism, biochemical and structural characteristics of the insulin receptor in 3T3-Ll fatty fibroblasts	15,200
Loretta Leive, Ph.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Phagocytosis of bacteria by macrophages: role of the polysaccharide of lipopoly- saccharide in interacting with macrophages and complement	5,000
Harvey B. Pollard, M.D., Ph.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Molecular basis of insulin secretion from pancreatic islet B cells	7,500
Matthew M. Rechler, M.D. Foundation for Advanced Educasion in the Sciences Bethesda, MD	Structure and biosynthesis of an insulin- like growth factor: multiplication stimulating activity	27,457
Harry Keen, M.D., F.R.C.P. Guy's Hospital Medical School England	Metabolic normalization and microvascular disease	23,789
George A. Bray, M.D. Los Angeles County Harbor- UCLA Medical Center Torrance, CA	Hypothalamic peptides in diabetes and obesity	22,212
David W. Hollister, M.D. Los Angeles County Harbor- UCLA Medical Center Torrance, CA	The collagens of normal and osteoarthritic cartilage	42,141

Principal Investigator and Institution	Title of Project	_1	Amount
David L. Rimoin, M.D., Ph.D. Los Angeles County Harbor- UCLA Medical Center Torrance, CA	The genetic heterogeneity of insulin dependent diabetes mellitus	\$	39,641
Alfred L. Goldberg, M.D. Harvard Medical School Boston, MA	The rapid degradation of insulin and other hormones in bacterial cells		18,448
John W. Angers, M.D. Human Immunology Foundation New York, NY	A diagnostic test for MS		-0-
Alvin H. Sacks, Ph.D. Institute for Medical Research San Jose, CA	Studies of the vascular problems related to diabetes		20,574
Linda C. Cork, D.V.M., Ph.D. Johns Hopkins Hospital Baltimore, MD	Infectious leukoencephalomyelitis of goats, an animal model of demyelinating disease		39,741
Richard T. Johnson, M.D. Johns Hopkins University Baltimore, MD	The pathogenesis of measles encephalitis in Lima, Peru		9,148
M. Daniel Lane, Ph.D. Johns Hopkins University Baltimore, MD	Regulation of the synthesis, processing and turnover of the insulin receptor in the liver cell		16,300
Shirley E. Poduslo, Ph.D. Johns Hopkins Hospital Baltimore, MD	Oligodendroglia: a study of its surface components		31,645
William L. Chick, M.D. Joslin Diabetes Foundation Boston, MA	Studies of pancreatic beta cells in the pathogenesis and treatment of diabetes		49,940
Robert A. Greenwald, M.D. Long Island Jewish-Hillside Medical Center New Hyde Park, NY	Effects of superoxide radical on connective tissues		28,017
Ralph A. Meyer, Jr., Ph.D. Marquette University Milwaukee, WI	X-linked hypophosphatemia (vitamin D-resistant rickets): a mouse model		36,599
Robert B. Colvin, M.D. Massachusetts General Hospital Boston, MA	Suppression of experimental allergic encephalomyelitis by anti-idiotypes		8,247

Principal Investigator and Institution	Title of Project	Amount
Henry J. Mankin, M.D. Massachusetts General Hospital Boston, MA	Demonstration of normal and osteo- arthritic chondrocyte heterogeneity using flow-through cytophotometry	\$ 8,191
Richard J. Wurtman, M.D. Massachusetts Institute of Technology Cambridge, MA	Effects of experimental diabetes on transport of hexoses and other substrates across the blood-brain barrier	22,517
John E. Gerich, M.D. Mayo Clinic and Mayo Medical School Rochester, MN	Control of somatostatin secretion in vitro	23,120
Vanda A. Lennon, M.D., Ph.D. Mayo Clinic and Mayo Medical School Rochester, MN	An immunologic approach to brain differentiation and myelinogenesis	47 ,4 55
F. John Service, M.D. Mayo Clinic and Mayo Medical School Rochester, MN	Metabolic normalization and microvascular disease	23,213
Thomas A. Huff, M.D. Medical College of Georgia Augusta, GA	The relation of non-enzymatic glycosylation of lens crystallin to cataract formation in diabetes	13,222
Gordon C. Weir, M.D. Medical College of Virginia Richmond, VA	Separation of cell types of the islets of Langerhans	13,808
Richard L. Drake, Ph.D. Medical College of Wisconsin Milwaukee, WI	Insulin's effect on changing levels of pyruvate kinase mRNA	11,000
Maniel J. McCarty, M.D. Medical College of Wisconsin Milwaukee, WI	Turnover of calcium pyrophosphate dihydrate crystal in vivo	25,250
William L. Duax, Ph.D. Medical Foundation of Buffalo Buffalo, NY	Molecular structure and biological activity of insulin I	26,400
Christian Schwabe, Ph.D. Medical University of South Carolina Charleston, SC	A novel osteoarthritis model	17,341
Gabriel Virella, M.D., Ph.D. Medical University of South Carolina Charleston, SC	Detection, isolation and characterization of circulating immune complexes in diabetic patients	31,720
	-6-	

Principal Investigator and Institution	Title of Project	Amount
David Hamerman, M.D. Montefiore Hospital and Medical Center Bronx, NY	A possible viral agent in rheumatoid arthritis: effects on glycosminoglycan synthesis by synovial cells	\$ 11,000
Eugene W. Straus, M.D. Montefiore Hospital and Medical Center Bronx, NY	Studies of the content and kinetics of CCK converting enzymes in obese rodent brains	14,438
Edward C. Franklin, M.D. New York University Medical Center New York, NY	Possible mechanisms for disordered immune regulation in rheumatoid arthritis and related diseases	16,140
Ira M. Goldstein, M.D. New York University Medical Center New York, NY	Oxygen-derived free radicals and inflammation	24,7 50
Mauro C. Dal Canto, M.D. Northwestern University Chicago, IL	Primary demelination produced by ts mutants of viruses: morphologic, immunohistochemical, immunological and virological studies	35,607
Norbert Freinkel, M.D. Northwestern University Chicago, IL	Effects of pregnancy on intermediary metabolism and diabetes	-0-
Howard L. Lipton, M.D. Northwestern University Chicago, IL	Chronic central nervous system infections in mice produced by human enteroviruses	33,984
Steven G. Krakowka, D.V.M., Ph.D. Ohio State University Columbus, OH	Canine distemper virus and multiple sclerosis	31,658
Jerry R. Mendell, M.D. Ohio State University Columbus, OH	Ultrastructural immunocytochemical localization of the P2 protein in peripheral nervous system	17,739
Charles F. Howard, Ph.D. Oregon Regional Primate Research Center Beaverton, OR	Diabetes in nonhuman primates	14,288
Richard L. Stevens, Ph.D. Robert B. Brigham Hospital Foston, MA	Somatomedin and insulin control of proteoglycan biosynthesis in the human chondrocyte	5,500

Principal Investigator and Institution	Title of Project	Amo	ount
Darrell Doyle, Ph.D. Roswell Park Memorial Institute Buffalo, NY	Transfer of the plasma membrane receptor for insulin from hepatocytes to cells not responsive to insulin	\$	7,325
Eva M. Kohner, M.D., F.R.C.P. Royal Postgraduate Medical School England	Metabolic normalization and microvascular disease	4	15,413
Floyd A. Davis, M.D. Rush-Presbyterian-St. Luke's Medical Center Chicago, IL	Effects of plasmapheresis on signs and symptoms in MS	4	10,294
Rodney Langman, Ph.D. The Salk Institute San Diego, CA	Reconstructing immune responsiveness in vitro from characterized cell lines	1	16,500
Robert P. Metzger, Ph.D. San Diego State University San Diego, CA	Increased concentrations of glycolate in urine and serum of diabetic subjects	-	-0
Donald E. McMillan, M.D. Sansum Medical Research Foundation Santa Barbara, CA	Studies of viscosity of diabetic serum	2	20 , 075
Willard P. VanderLaan, M.D. U. J. Lewis, Ph.D. Scipps Clinic and Research Foundation La Jolla, CA	Diabetogenic peptides of the arterior pituitary	•	54,650
John H. Vaughan, M.D. Scripps Clinic and Research Foundation La Jolla, CA	Thoracic duct drainage in rheumatoid arthritis	2	27,849
John A. Hamilton, Ph.D. Sloan-Kettering Institute New York, NY	An in vitro model of rheumatoid arthritis	1	14,684
William C. Dement, M.D., Ph.D. Stanford University Stanford, CA	Sleep, diabetes mellitus, and the autonomic nervous system	2	24,334
Leslie J. Dorfman, M.D. Stanford University Stanford, CA	Clinical neurophysiological studies in multiple sclerosis and related disorders		-0-

Principal Investigator and Institution	Title of Project		mount
Robert T. Wall, M.D. Hunter Little, M.D. Stanford University Stanford, CA	Intensive plasmapheresis in diabetic microangiopathy	\$	11,000
Stephen G. Waxman, M.D., Ph.D. Stanford University Stanford, CA	Studies on neuronal properties in demyelinating disease		37,910
Milton Alter, M.D., Ph.D. Temple University School of Medicine Philadelphia, PA	B cell antigens in Israeli patients with multiple sclerosis		-0-
Ronald A. Pieringer, Ph.D. Temple University School of Medicine Philadephia, PA	The association of galactosyl diacylglycerols with multiple sclerosis		29,226
Donald R. DiBona, Ph.D. University of Alabama in Birmingham Birmingham, AL	Structural correlates of diabetic nephropathy		6,109
Edward J. Miller, Ph.D. University of Alabama in Birmingham Birmingham, AL	Comprehensive evaluation of type II procollagen from cartilagenous tissue		6,079
Caroline S. Pace, Ph.D. University of Alabama in Birmingham Birmingham, AL	Implementation of a new procedure for determining the molecular requirements for insulin release		24,543
Martinez J. Hewlett, Ph.D. University of Arizona Tucson, AZ	Molecular aspects of bunyavirus infection in neural cells		15,906
Robert I. Mishell, M.D. University of California, Berkeley Berkeley, CA	Induction of resistance to the immuno- suppressive effects of glucocortico- steroids by bacterial peptidoglycan		34,966
M. Eric Gershwin, M.D. University of California, Davis Davis, CA	The pathogenesis of avian scleroderma		11,000
Thomas C. Cesario, M.D. University of California, Irvine Orange, CA	Detection of interferon in serum and synovia fluid of patients with rheumatic disease	1	15,014

Principal Investigator and Institution	Title of Project	 Mount
Gale A. Granger, Ph.D. Jim Kostergaard, Ph.D. University of California, Irvine Irvine, CA	Demonstration of lymphocyte effector molecules in the tissue destructive lesions of rheumatoid arthritis	\$ 22,992
David T. Kingsbury, Ph.D. University of California, Irvine Irvine, CA	Molecular probes for the detection of mycoplasma and chlamydia in rheumatoid arthritis	28,667
Lewis M. Slater, M.D. Dniveristy of California, Irvine Irvine, CA	Immunogenetics of human diabetes	40,464
Rodney Bluestone, M.D., F.R.C.P. University of California, Los Angeles	Cellular regulation in hyperuricemic nephropathy	15,265
Josiah Brown, M.D. University of California, Los Angeles	Ontogeny and typing of histocompatibility antigens in human fetuses	14,180
Yi-Han Chang, Ph.D. Carl M. Pearson, M.D. University of California, Los Angeles	Effects of colchicine on functions of polymorphonuclear leukocytes in patients with gout	20,919
George W. Ellison, M.D. University of California, Los Angeles	Drug studies in multiple sclerosis	81,137
John H. Fessler, Ph.D. University of California, Los Angeles	Basement membrane synthesis by blood vessel endothelial and other cells	14,295
Solomon A. Kaplan, M.D. University of California, Los Angeles	Respiratory distress syndrome in infants of diabetic mothers	18,146
Seymour R. Levin, M.D. University of California, Los Angeles	Insulin infusion and white cell ATPases	10,000
Timothy A. Miller, M.D. University of California, Los Angeles	Factors which influence survival of autogenous muscle grafts and muscle regeneration	11,000
Lawrence W. Myers, M.D. University of California, Los Angeles	Immunological studies in multipre sclerosis	-0

Principal Investigator and Institution	Title of Project	Amount
Jack G. Stevens, D.V.M., Ph.D. University of California, Los Angeles	The genetic and molecular basis for neurovirulence in herpes simplex viruses	\$ 12,314
Jack G. Stevens, D.V.M., Ph.D. University of California, Los Angeles	Pathogenesis of Marek's Disease: A model for the Landry-Guillain-Barre Syndrome	12,919
Wallace W. Tourtellotte, M.D., Ph.D. Hans Link, M.D. University of California, Los Angeles	A search for MS antigen utilizing kaotropic reagents	14,300
Marshall R. Urist, M.D. University of California, Los Angeles	The mechanism of bony overgrowth in arthritic disease	30,000
Stafford L. Warren, M.D. University of California, Los Angeles	Search for an active agent in rheumatoid arthritis	44,450
Jack A. Alhadeff, Ph.D. University of California, San Diego	Characterization of altered glycoprotein metabolism in human diabetes	15,180
Theodore Friedmann, M.D. University of California, San Diego	An approach to the isolation and charac- terization of the HGPET gene	8,250
David A.Gough, Ph.D. University of California, San Diego	Development of an implantable gluccse sensor	5,000
Gordon H. Sato, Ph.D. University of California, San Diego	Growth of normal pancreatic beta cells in culture and the role of insulin in serum-free medium	7,276
J. Edwin Seegmiller, M.D. University of California, San Diego	Ochronotic arthritis and other forms of hereditary degnerative joint diseases	-0-
Nathan J. Zvaifler, M.D. University of California, San Diego	Cryoglobulins in the rheumatic diseases	-0-
Allen I. Arieff, M.D. University of California, San Francisco	Lactic acidosis: effects of therapy	34,109

and Institution	Title of Project	Amount
Michael Fischbach, M.D. University of California, San Francisco	Idiotype-anti-idiotype in murine lupus using monoclonal hybridoma induced anti-DNA antibodies	\$ 24,750
Ira M. Goldstein, M.D. University of California, San Francisco	Oxygen-derived free radicals and inflammation	8,627
John Heuser, M.D. University of California, San Francisco	3-D visualization of freeze-dried cells and molecules	33,000
Kenneth P. Johnson, M.D. University of California, San Francisco	Pathogenesis of multiple sclerosis	13,171
Robert R. McKendall, M.D. University of California, San Francisco	Cytotoxicity in multiple sclerosis	8,123
Jackson B. Pickett, M.D. University of California, San Francisco	Effect of insulin on neuromuscular transmission	11,764
William E. Seaman, M.D. University of California, San Francisco	Autoimmunity in androgen resistant BXSB mice	8,227
Marvin D. Siperstein, M.D., Ph.D. Kenneth R. Feingold, M.D., Ph.D. Millie H. Wiley, Ph.D. University of California, San Francisco	Derangement of cholesterol metabolism	39,54
Barry G. W. Arnason, M.D. University of Chicago Chicago, IL	Nonsense antibodies in CSF in multiple sclerosis	20,45
Arthur H. Rubenstein, M.D. University of Chicago Chicago, IL	Metabolic normalization and microvascular disease	19,99
Carol M. Brownscheidle, Ph.D. University of Cincinnati Cincinnati, OH	The spontaneously diabetic BB rat: an animal model for the study of the effects of maternal diabetes mellitus on pregnancy, fetal maturation and neonatal health	7,84
Jerome H. Herman, M.D. University of Cincinnati Cincinnati, OH	Evaluation of mechanisms modulating the activation and release of chondrocyte proteinase activity	21,34

Principal Investivator and Institution	Title of Project	Amount
Jack S. Burks, M.D. University of Colorado Health Sciences Center Denver, CO	Transmission studies in multiple sclerosis	\$ 113,030
Henry N. Claman, M.D. University of Colorado Health Sciences Center Denver, CO	Immunologic responses to insulin	26,643
John S. Goff, M.D. University of Colorado Health Sciences Center Denver, CO	Investigation of diabetic diarrhea	9,900
Sylvia J. Kerr, Ph.D. University of Colorado Health Denver, CO	Methylation of membrane components and insulin action	16,084
Jerrold M. Olefsky, M.D. University of Colorado Health Sciences Center Denver, CO	Mechanism of insulin resistance in obesity	35,052
John E. Repine, M.D. University of Colorado Health Sciences Center Denver, CO	Killing graft macrophages with hyperoxia may facilitate pancreas transplantation in patients with diabetes mellitus	8,485
David W. Talmage, M.D. University of Colorado Health Sciences Center Denver, CO	The abrogation of immune rejection of endocrine grafts	16,354
Paula Dore-Duffy, Ph.D. University of Connecticut Health Center Farmington, CT	Lymphocyte adherence in multiple sclerosis	27,041
Kathrin A. Krakauer, Ph.D. University of Connecticut Health Center Farmington, CT	Synovial cell endocytosis and intracellular digestion: a study of the contribution of synovium to the turnover of joint constituents	11,409
Steven E. Pfeiffer, Ph.D. University of Connecticut Health Center Farmington, CT	Temperature-sensitive lines of myelinating oligodendroglia and Schwann cells	18,441

Principal Investigator and Institution	Title of Project	Amount
Marvin L. Tanzer, M.D. University of Connecticut Health Center Farmington, CT	The synthesis, assembly and secretion of procollagen: A biochemical and genetic approach	19,128
Laurence S. Braude, M.D. Jose G. Cunha-Vaz, Ph.D. University of Illinois at the Medical Center Chicago, IL	Studies in retrobulbar neuritis and multiple sclerosis	11,000
David L. Camenga, M.D. University of Maryland Baltimore, MD	Canine distemper virus induced demyelination: an animal model for multiple sclerosis	41,177
Arthur A. Like, M.D. University of Massachusetts Worcester, MA	Studies of the spontaneous juvenile diabetic syndrome of the bio breeding laboratory rat	42,591
David S. Howell, M.D. University of Miami Miami, FL	Role of matrix vesicles in chondrocalcinosis	28,916
Duane R. Schultz, Ph.D. University of Miami Miami, FL	Immunological and biochemical studies of a polysaccharide in an ant venom (Pseudomyrmex sp.): Its use for rheumatoid arthritis	28,438
Jack L. Kostyo, Ph.D. University of Michigan	Growth hormone: structure-function relationships	32,450
Thomas J. Schnitzer, M.D., Ph.D. University of Michigan Ann Arbor, MI	Patnogenesis of avian reovirus arthritis	13,860
Jose Barbosa, M.D. University of Minnesota Minneapolis, MN	Study of nondiabetic sibs with two or more diabetic siblings	11,000
Steven D. Douglas, M.D. University of Minnesota Minneapolis, MN	Immunology and function of mononuclear phagocytes in rheumatoid arthritis	9,625
T. Z. Csaky, M.D. University of Missouri-Columbia Columbia, MO	Epithelial sugar transport and diabetes mellitus	21,450
Pierre Robitaille, M.D. University of Montreal Canada	Relationship between sterility and sperm specific nuclear antigens in insulin- dependent diabetes	11,000

Principal Investigator and Institution	Title of Project	Amount
K.G.M.M. Alberti, M.D. University of Newcastle Upon Tyne England	Metabolic normalization and microvascular disease	\$ 5,723
R.Philip Eaton, M.D. University of New Mexico Albuquerque, NM	Glucose homeostasis in normal man, obesity and diabetes	-0-
R. Philip Eaton, M.D. William J. Spencer, Ph.D. University of New Mexico Albuquerque, NM	Bioengineering and biomedical development of a programmable/implantable insulin- delivery system	38,813
Ralph C. Williams, Jr., N. University of New Mexico Albuquerque, NM	Projects related to immune mechanisms in the connective tissue diseases	28,700
Wesley W. Bullock, Ph.D. University of Oregon Health Sciences Center Portland, OR	Regulation of human neutrophils by monosaccharide-inhibitable lymphocyte signals	8,280
Steven D. Douglas, M.D. University of Pennsylvania Philadelphia, PA	Immunology and function of mononuclear phagocytes in rheumatoid arthritis	19,250
Kathrin A. Krakauer, Ph.D. Univeristy of Pennsylvania Philadelphia, PA	Synovial cell endocytosis and intracellular digestion: a study of the contribution of synovium to the turnover of joint constituents	6,826
H. Ralph Schumacher, Jr., M.D. University of Pennsylvania Philadelphia, PA	Articular chondrocalcinosis: factors in crystal deposition	-0-
Donald H. Silberberg, M.D. University of Pennsylvania Philadelphia, PA	Role of alpha-fetoprotein in modifying in vitro CNS demyelination	9,188
Robert Ader, Ph.D. Nicholas Cohen, Ph.D. University of Rochester Rochester, NY	Behavioral processes in the immuno- pharmacotherapy of autoimmune disease	8,227
Glenn L. Wilson, Ph.D. University of South Alabama Mobile, AL	The role of N-nitroso compounds in insulin-dependent diabetes mellitus	5,869

Principal Investigator and Institution	Title of Project	Amounc
M. Michael Appleman, Ph.D. University of Southern California Los Angeles, CA	Regulatory mechanisms for lymphocyte activities	\$ 10,010
Karl Folkers, Ph.D. University of Texas at Austin Austin, TX	Synthesis of interferon and fragments	28,036
Karl Folkers, Ph.D. University of Texas at Austin Austin, TX	Cooperative research on the synthesis of peptides related to the human growth hormone and having diabetogenic activity	63,649
Grady F. Saunders, Ph.D. University of Texas System Cancer Center Houston, TX	Biosynthesis of glucagon	7,958
Peter Stastny, M.D. University of Texas Health Science Center Dallas, TX	HLA and the immune response in man; predisposition for rheumatoid arthritis	18,150
Donald H. Nelson, M.D. University of Utah Salt Lake City, UT	Study of the mechanisms by which corticosteroids produce their harmful effects when used in the treatment of arthritis	-0-
Donald H. Nelson, M.D. University of Utah Salt Lake City, UT	Relation of insulin effects on phospholipid metabolism to the increased incidence of cardiovascular disease in diabetes mellitus	16,468
John R. Ward, M.D. University of Utah Salt Lake City, UT	Etiology of human rheumatoid arthritis	-0-
Edward S. Horton, M.D. University of Vermont Burlington, VT	Effects of exercise on insulin resistance in muscle	12,636
Glenn L. Wilson, Ph.D. University of Vermont Burlington, VT	The role of N-nitroso compounds in insulin-dependent diabetes mellitus	11,000
Alan D. Rogol, M.D., Ph.D. University of Virginia Charlottesville, VA	Isolation and purification of a low molecular weight insulin antagonistic peptide from bovine pituitaries	4,981
William P. Arend, M.D. University of Washington Seattle, WA	Neutral protease secretion in human monocytes and macrophages	28,680

Principal Investigator and Institution	Title of Project	!	Amount
John W. Ensinck, M.D. University of Washington Seattle, WA	Glucose 'control' in diabetic humans using a glucose controlled insulin infusion system	\$	14,455
Wilfred Y. Fujimoto, M.D. University of Washington Seattle, WA	Epidemiology of maturity-onset type diabetes and its morbid consequences		8,004
Daniel Porte, Jr., M.D. University of Washington Seattle, WA	The role of pancreatic islet cell electrical activity in glucose-induced insulin release		7,774
R. Paul Robertson, M.D. University of Washington Seattle, WA	Regulation of prostaglandin E receptors in pancreatic islet plasma membranes		14,458
Robert H. Williams, M.D. University of Washington Seattle, WA	Investigation pertinent to collagen changes in some common disorders		-0-
John Dupre, M.D. University of Western Ontario Canada	Metabolic normalization and microvascular disease		19,939
Thomas H. Steele, M.D. University of Wisconsin Medison, WI	Renal urate handling: relationships between hypertension, hyperuricemia, and the pathogenesis of gout		27,880
G. Gry Dodson, Ph.D. University of York England	Molecular structure and biological activity of insulin II		35,640
Claes Hellerstrom, M.D., Ph.D. Uppsala Universitet Sweden	Transplantation of fetal pancreas to diabetic patients		8,206
Paymond L. Woosley, M.D., Ph.D. Vanderbilt University Nashville, TN	Drug-induced lupus erythematosus: investigation of the role of reactive metabolites		15,800
Travis C. McQuire, D.V.M., Ph.D. Washington State University Pullman, WA	Studies on caprine arthritis- encephalitis		7,500
John Heuser, M.D. Washington University St. Louis, MO	3-D visualization of freeze-dried cells and molecules		17,345
Paul E. Lacy, M.D., Ph.D. Washington University St. Louis, MO	Allografts of isolated islets of Langerhans		82,667

Principal Investigator and Institution	Title of Project	 mount
David W. Scharp, M.D. Washington University St. Louis, MO	Isolation and culture of islets for transplantation	\$ 75,723
David W. Scharp, M.D. Paul E. Lacy, M.D., Ph.D. Washington University St. Louis, MD	Studies on the isolation and transplan- tation of fetal pig islet tissue	19,250
Benjamin D. Schwartz, M.D., Ph.D. Mashington University St. Louis, MD	A bio henical approach to study the relationship between HLA antigens and arthritic diseases	16,816
John L. Trotter, M.D. Mashington University St. Louis, MO	Immunosuppression in multiple sclerosis	30,933
Margo P. Cohen, M.D. Mayne State University Detroit, MI	Cultured retinal microvessel cells: a model for study of diabetic retinopathy	15,116
P. Arthur McMorris, Ph.D. The Wistar Institute Philadelphia, PA	Effect of viruses on myelin functions in vitro	8,350
John Booss, M.D. Yale University New Heven, CT	Immunosuppression of B cell function in multiple sclerosis	24,512
Philip Felig, M.D. Yale University New Haven, CT	The metabolic response to excreise in normal and diabetic humans	49,908
Stephen E. Malawista, M.D. Yale University New Haven, CT	Clinical and laboratory studies of arthritis	-0-
Robert S. Sherwin, M.D. Yale University New Haven, CT	Metabolic normalization and microvascular disease	35,9 53
Joan A. Steitz, Ph.D. Yale University New Haven, CT	Structure-function studies of small RNPs precipitated by the lupus antibody La	7,212
Hunter L. Little, M.D. Zweng Memorial Retinal Research Menlo Park, CA	The effect of constant subcutaneous infusion of regular insulin on the course of diabetic retinopathy	11,000

Recipient		Amount
Dartmouth Medical School Hanover, New Hampshire	\$	171,733
Michigan State University East Lansing, Michigan		266,828
Southern California Tissue Society		500
March of Dimes		100
Grant Hospital Library Fund		100
University of Arizona		500
International Society of Endocrinology		1,500
Perspectives in Biology		350
American Diabetes Association - So. Cal. Affiliate		225
The Aesculapians		200
Hanot Foundation		10
Visiting Nurse Association		100
. Regents of the University of Southern California		100
Reed Neurological Research		500
Arthritis Foundation		100
American Thyroid Association		300
National Multiple Sclerosis Society		100
Eisenhower Medical Center Diabetes Program		1,000
7th Parathyroid Conference		500
American Diabetes Association		125
National Multiple Sclerosis - N.Y. Chapter		200
Stanford University School of Medicine		100,000
Research to Prevent Blindness		100
Foundation Center		2,500
Alzheimers Disease		100
Western Association of Physicians		1,000
Family Renewal Center, Fairview - Southdale Hospital		10,000
Aloha House		2,000
United Way	-	10

TOTAL CONTRIBUTIONS, GIFTS, GRANTS

\$ 4,787,086

All grants are for medical/scientific research. No recipient is related to The Kroc Foundation in any way.

POSS CONTRIBUTIONS - PAPE 1. LINE 1 RAY A KROC 110- 295H 1939 YILLA LA JOLLA DRIVE 116- CASH JUITE 208	Co 1 A	C. B.C	610
RAY A KROC 110- 295H 1939 YILLA LA JOLLA DRIVE 116- CASH JUITE 208	CONTRACTOR CONTRACTOR SERVICES AND ADMINISTRATION OF THE PROPERTY OF THE PROPE	Col. AVC	
1939 YILLA LA JOLLA DAIVE "16. CASA JUITE 208	4		+ 6, 0
30.78 408	can be the property of the pro	-	
		-	na na kata na
LA JOLLA CA 12031			de la constanta de la cons tanta de la constanta de la consta
	50000		
HER Moome : MAN 1. LINE 12	232 313	232 313	
FILM AND BOOK PECCEPTS	55 232		
GRANT REFLUES	2364	2364	
Misceri gatous	4369		
	289 9.9	234 677	
es - Part 1, Line 19		and the second of the second o	
PAYROLU PAREL	12 548	3510	10031
Excise TARES	291 665		129/665
3300 /110			
	3.4 213	25.0	301703
		-	

IER EXPENSES - PART I, LIME 22			***************************************
NUTO ETPENSE	347		349
Outs And Subscriptions	5461		3461
Confectine Extense	193 925		193 925
OFFICE EXPENSE	11 231	2246	1915
PUBLICATION EXPENSE	223840		223 32.
TELEPHONE AND UTILITIES	14 310	1431	12 379
TRAYED AND ENTERTHINMENT	31675	6335	2534.
Library Excense	/ • • 7		1007
MAINTENANCE AND REPAIR	10077		10 077
MISCELLANCOUS EARTHSE	1003		1003
INSURANCE ÉNTENSE	9, 492		9, 492
OPERATION CHEN EXPENSE	979 126		979 126
And the second s			
	562976	10012	1552767

						YEAR ENDED 14/81/8-				
		12/1			CO - NON 22 PM	14/3/10-				
1	<i>der</i>			017			9mi	C		
47 2	P. L.	76	50							
				-	ļ	CONTRACTOR CONTRACTOR	ACCOMPANIANCE DESIGN		499	
-				-	-	and the state of t			A STATE OF THE PARTY OF THE PAR	-
	-		<u> </u>	-		CONTRACT PROPERTY.	ALC: UNKNOWN BY		The second second	
			-	-		500			.,,	3,7
-	+				 			-+		-
†	†		1		†			,	721	. "
	we 6		 							-
				-		165			166	•••
				-		500			CONTRACTOR	A CONTRACTOR
				-		2	000		220	
			100			Sao	900		¥ 7¥	375
				•		5	•••		475	
				-		500			471	75.
				-		5	•••		495	• • •
				<u> </u>		500	•••		s.,	•••
				-		40.	•••		۵.,	
			ļ							
				-			+		521	123
										-
				_		<i>y</i>				46.
				-			SECURIOR SECTION		474 ESTABLISHED BOTTOM CONTROL OF THE	A STREET, SQUARE, SQUARE,
4			1			procession restriction of	CONSTRUMENTAL CONTRACTOR AND ADDRESS.	,	CONTRACTOR STREET	Section 1
-		٠٠ ١	STATE OF THE PARTY STATE OF THE	AND RESIDENCE	Control Control Control				74 4	66
					Section 1				-	
										<u> </u>
		******								-
				766	773				• 77	267
	almater acous		policie sing a petrop col		********					
				AND DESCRIPTION OF THE PARTY OF	According Systems 2	-				723
		-		MICHIGAN CHANGE CO.	STY - 1233-078-078-0				13	.4.
166				149	625					•
			Produces America	.11	551					.61
		and the last of th	and the second second							
								100		-
-		-	-	Section of the least					-	1
	37. 4.					## Cast ##	### Coat 50 50 50 50 50 50 50 5	1mr	### Coar ### Coar ### Coar ####################################	### Cast Amp Cast #### Cast ####################################

FORM 204 P

REVISED 9/71

TEMENT NO. 3 (99. Pr.) Ares des 2	Same		YEAR ENDED 13/31/30							
		tor "	/0/179 Co.			17	12/0	/1.	.,	
VENEMBURY IN GAMBAIL STOCKS. BAP	or.	Lenk 7								
dreaming Acoustices				-		1	•			7.4
Consce. Inc	1 6			77	***		•		7,	111
Aus · Benestator Gae	The second second	• • •		24	447	5	•		74	74
				-1		1			119	, 7.
General Execisis	7	5		6,	354	35.			6,	25.
				•		700	•			1 2
NALL: BURTON NEWLETT PACKARD				6.0	747		•		61	73
				•		5 25	•		16.	7.
Moseriau Core or Acresica				•		3	•		262	
Nugary Took G		•••		11.	259	3			,,,	25
180	CHARLES THE RESIDENCE	5	Annual Control of the	111	AND DESCRIPTION OF THE PARTY OF	45.			11.	15
Jameson . Journson	ting charife and the		ACCESSABLE MELITERING CONTRACTOR OF	166	ACCOMMENSAR O	7.0	Westerner Communication		166	+1
Littum Inquerques	THE REAL PROPERTY.		1	146	giotechnicosty &	300			146	Charles Services
SCHOOM BERGER LTD	-	5		NO. OF THE PERSON NAMED IN	.,,	500			152	1
STANDARD DIE OF MUIANA	1	 • • -	\dashv			70.	manufacture descriptions		115	
STANDARD OIL OF THIS	+	+	1			200	many characters		169	Section 1
TEAS WAIRWARMS			+	125		4	Marian Company		, 25	
Times Misses	+•	+	-	143	· · ·	, 31	MINISTER STREET, SQUARE, SQUAR		2,3	T.
WONG LOADERTONILL		+-+			-		Comment of the Control of	***************************************	170	1
Wagnes Communications	-	 	-	-	5.0	7 - 4	And the second		15	1
WEITERN BANCORPORATION		•••		73	***	- 6 -	a strings controlled	-	, + 0	-
STEIN HOL & FARMAM CAPITAL OF FUND		+			-	/0 0			121	
STEIN ROE SPECIAL FUND		- , ,		ACTOR DESIGNATION OF THE PERSON OF THE PERSO	+13	3, 09			349	-
SPEIN POR UNIVERSE FIND INC		1				4 9 1	The second second	—	-	-
Mc Jonaros Concondition		1000	+7	and purification to the	500	7.0	•	+ 30	• 6 4	+-
Baisson Maids Co	-	1			705	-		-		-
Dowgeosod Co		1000			947			-		+-
PRILLIP MORRIS INC		500		THE RESERVE OF THE PARTY.	217			-	<u> </u>	+-
TEXTRONIA	Consider Michigan Processing	5		-	171	30	See	1 7.	7460	+,
STEIN ROLE CHAN RELIENCES	+333	472		317	172	9.0	500 00	tum	1-11-3	t
	4	1-1		.77	¥97		_	37	841	7
	1	111					_			
		+-+			-			-		1
								e and the second second second		+
THER LIGARLITIES - PART III. LINE 17									!	#
FEBERAL ESCISE TAS PARAGE				ALEX CLASSICS CLASS	200				211	_
Accourt Parent Trees					126			-	-	, ¥
		11			4			-	+	-
		4		101	126	-	_	ALIENSANCE:	47	+
		+			+			1	†	1
		++			+	The second second		1	-	
		++		-	De la Granda			-		

Schedule of Capital Gains too latter

	INT NO					No.			Anna di Anna	T)_ <u>'4</u>		
	F Yu diftion	16w	dere #•	dere Sono		er A.	cé		Cost		Swe	Gain as Tei			ss > 6	~
	BRISTON MYERS	,	7/75	4/0/0.	167	369		141	703						/1	66
CONTRACTOR OF THE PROPERTY OF THE	Coumain Gas System	,	4/0.	"/9/00		744		AND DESCRIPTION OF THE PARTY OF	•75		.,		, 1		present waterstellings	
ALL DESCRIPTION OF THE PARTY OF	donacoson G. INC	م	175	4/0.	STREET, STREET	4.6		-	747					-	72	¥7
	Me downer's Core	8	1/19	V/0.	OTONOON HOMEON	419			-					,	66#	A
100 (C) - 190 (120 (HITE)	Me DOWALD'S CORP	۷	7/79	40.	attendentionstation	476			-		es alterior			The Control		a secondario
SERVICE CONTRACTOR	Me Donger's Coar	۵	7/79	4/1.	3076	A CONTRACTOR OF THE PARTY OF TH			-				Mary Colder Secretary	,	176	A CONTRACTOR OF THE PARTY OF TH
THE PERSON NAMED IN	Me Double's Gar	0	7/79	-/1-	Concession Commission in Co.	713		Market States		1				g	64	93
SHIPPERMENTER	Me demands Come		7/79	1/0.	6351	*****			-		Marian Marian - Andrews			6	131	55
S. Attention to Constitution	Private Modais INC		1/75	14.0/00	Contract of the last of the la	441		134	207					and the second	16	31
	Fentaments	-	71.75	·/·	THE PERSON NAMED IN COLUMN 2 I	5. 1		Section of the section of	17,					ige on account district		
	***************************************													M.2000 Ph.0000		T
See	Res Species Fune	Car		Gara	4		11.							******		54
<u> </u>		****	and the second													
		and the second second	and the second second		********			Marie Charles Construction Printers	-	1	< 1	1317		14.	7.1	3.
		**************************************		Machiner Charles of the Charles of the Charles				Marie State			- province and			,641.101.000000		
					A CONTRACTOR	1			- I							
		CONTRACTOR CONTRACTOR	NAME OF TAXABLE PARTY.	Committee of the State of the S	- Children Control		-	7. 7	44	GA.	,	Total Composition		/4	7	17
		******************		A MANAGE STREET, STREE	-	# All and a roundered	-	es a sierana	A CONTRACTOR OF THE PARTY OF TH	THE RESERVE	all section and the section of	TO THE OWNER OF THE PARTY OF TH				
			-	The second or second or	NAME OF THE PARTY.	1	\$ management and	Adoption new providing on	admin X man Small	1	HE CONTRACTOR	CHOOL SHAMMER THE REAL		Beg state or vidence, J	- securios de la constitución de	T
0.00					1	1	1	- Anna Carlotte	Management of		No. 400 in the special state of the special state o			-		-
•				delica in a transmission of a resident	-			***********	***************************************		Andrew Common to the	CONTRACTOR CONTRACTOR		- Strater and the room that	*constrainment	1
•		Marian a significant		THE STREET OF THE PARTY NAMED			1	Augustine commentation	CANADA CONTRACTOR	-	Contractor of the Assess	e-rup : mpdat, mmens		6641 - NO.5704110114		1
				The conduction of the latter o	-		1	erichemissische Specimene	-	-	Edenations control			ACTION CO.		1
						 	1	and the street of the street	and the second second	-	NOR CHICKNEY CHAR	ADD			-	1
				soldenings over the constraints of the con-	-	-	1	Magazi Later con arbesta	- marin	The same of the same	SCHOOL ST. SHEET			the same of the contract of the		1
				COMMUNICATION OF STREET	1	†	 	-	- Commence Commence		COMPANY PROPERTY.					-
		to the same of the same of the		A CONTRACTOR OF THE PARTY OF TH	-	-	1	AND DESCRIPTION OF THE PARTY OF		1	to the population			ALICE AND COMPANIES		1
				no proper alle planting and planting	+	+	+	†	***********	†		-	-			1
		-	Marie de colonies de la constante de la consta	Andrew Comment of the Party	-	 	1	<u> </u>	***************************************				*****************		- co-opin-s-norm	•
				CONTRACTOR PROPERTY.	-	-	1	†		-	andronen mo	en e	-	Corpor (Maked) etc	- MARTING ALL ARE	n i de la companya de
					-	 	1	-	-	1		•		NAME OF TAXABLE PARTY.	1	1
	The boundary of the second sec					+	 	 	1	1			-		-	†
						+	+	<u> </u>	-	-	-					-
-		-			-	+	 	 	-	-	-	and a second	-			
TOTAL PERSON					+	+	+		†	+		-	<u> </u>	**********	1	1
					1	†	+	†	1			1			-	1
		A ROMAN PARKET AND THE	Water to the Sales	and the second s			1			04.7 PM	1				1	
-			-						-		BA-18 11		-		-	1
		Andrew Control of the		-			1	-	†	and a second second	(A) (B) (B) (A) (A) (A) (A) (A)		1		1	1
					+	+	+		1	-	Mar en		-		1	1
				-	+	+	+		+	+	A CONTRACTOR OF CONTRACTOR	1	-	1	1	
			-	CONTRACTOR OF STREET		-	+		1	-	e francismo-man	1			1	-
					+	+	+	 	1	1	† -	†	†		1	+
granic salaras						1			8	1		1	1	1	1	
					1	+	+	1	1		-	1			T	
					1	-	1			-					-	

ATEMENT NO. 3		ers part of a sec					HEAR EMPE	0 /4/3//10
OFFICERS AND DIRECTORS . PART YI -	2							
	 			Separation (Separation)	4.0 F	* ************************************		
Mame 100 Accaess	7.74	• //	<u>ع</u> د	Black	8,7 6	**	EXPENSE ACCT	Balansare
RAY A KHOG	Congr	14~	e 100		None		Nene	No.71 &
1939 Yours LA Jours Daire. Juice 203	Conna	. 0.0	1004					
4 Josep CA 92037	- 1000	.~4						
Ronear L Mess	PROSIN	147		,,	556		13 415	47 444
Pa Bos 547	THE STREET STREET, STREET	6 0 75						
Squira Ymes. CA 9346.	. 604	EN ESSENCE						
Joon & Kase	Vice Pe		241		News		~~~4	~~~
8989 Yours la Jours BRIVE, SUITE 208	.0.	20 25 25 25 25 25 25	CHRISTIAN .					
4 Jours, CA 72-37	- 124	<u>r </u>		MILE YES		a hi sposyona		
Fall L Tuanta	Y.C. T				None	1		~~~
% Me JONALD'S CORPORATION		eter	BETA SERVICE TO BE 3	Marie Control of Control of Control			to the second se	
Mc Downer Agen, Con Adoor , 16 40141	· No.	Contract Contract			•			
LORRANGE E GROS	Jane				~· ~!		w.~ c	W. W. E
17715 GULF BLVO, 0 842	All the second s		Comments of the	COMMON AND STREET	•		The second secon	
Resemeton Syones, FLA 31708	- ~-	Contraction Contract	A CONTRACTOR OF THE PARTY OF TH	Control of the Control			Mark the second of the second of the second of	
BOLLOGO F SMILH	Secas	, 4 e v	•	MINISTER SECTION	7006			* 0 ~ 1
Po. dos 2000		ecre		E SAMPLE COLOR				The state of the s
Jan Diece Ca 12:20		~ · ~ ·		Marine Control	•			
GA HOSSMAN	933,50				~~~	-	~~*	and the second s
P939 Young Ly Joung Cares. July 203	Secue	Signature and		Season sees the state of		-		
A Joseph CA 920-37	- 20	111111111111111111111111111111111111111			A CONTRACTOR OF THE	-		
	455.5				443	-		,,,,,,
Joan lewin	Secar	Same named in	-		* - PE - P	******		***
Yo Box 547 Sawia Ywee. CA 1846.	. 40			and the second s	and continues	S COMMENSO	and a management of the state of state of the state of th	
		Marillananan masananana				to the second		
	Maria Maria Maria de	and the second second		es persona		C Security Control		59 655
					-	-		
				ļ	-	-		
	1		 	1	+	1		1 1 1

SUPPLEMENTAL DEPRECIATION

STATEMENT SD

Year -3/8//3-

Supplement to 920 PF Page / of /

lo.	DESCRIPTION OF PROPERTY	Date Acquired	¥8.×	Cost or Other Basis (Less Land)	ADJUSTMENT	TS TO BASIS	Depreciable Basis	Prior Depreciation	Remaining Cost		þi	Rate	Deprociation This Year
	FURNITURE + FIXTURES	4		J	e da migati res.	Only	and the second			÷			
		YAR		45116		er en outenstanding	45116	2.,,8	22777		104		5848
	FURNITURE + FIRTURES			22306	-		44346	47	17595	*	-44		1114
	TRANSPORTATION EQUIP	1/3.175		6190	1		6970	6190		54			-
	MEDICAL RESEARCH FOUR	2977		14416			,4416	Jin		1.	5.,.		/470
										-			
										-			
										L			
		1						 		+			
										1			
										1			
			 			• • • • • • • • • • • • • • • • • • •				+	-		
		1	L					·		1	1		
										-			85
	METHOD CODES	TOTALS		11299			\$\$79\$	36324	52471				2052
3	-200% DECLINING BALANCE -150% DECLINING BALANCE -125% DECLINING BALANCE -SUM OF THE YEARS-DIGITS						Add 21	1% additional depre (Not to exceed	szooo and \$400	pur c D lim	hased	11415 year	
, 6	OTHER							TOTAL D	EPRECIATION	1 T	HIS '	YEAR	9054.

Form 990-AR

1980 Annual Report of Private Foundation

THE KAOC FOUNDATION

Name

Under Section 6056 of the Internal Revenue Code

This Annual Report and the annual return of the foundation filed on Form 990-PF are available for public inspection. Consult an Internal Revenue Service office for further information.

FRESNO SERVICE CENTER

05 13 8 1 NO.

INTERNAL REVENUE SERVICE
FRESNO, CA

Department of the Treasury Internal Revenue

Annual report for calendar year 1980, or fiscal year beginning Home of organization		, 1980, and ending	. 19 Hification number
THE KROC FOUNDATION Address of principal office			25258
Po. Bor SAT, SANTA YMEZ. CA 134			
W books and records are not at above address, specify where they are	6 •		
MASSINGER, MCCOUNTANTS, INC., 600 is ST. Suite	MEDITORU HREMAN,	Name of princ	ipel officer of found
Public inspection (see instruction C):	rase, UAD DIEE.	C4 7215 / 104 104	AT L MASC
(a) Enter date the notice of availability of annual report a	ppeared in newspaper	MAT 5 . 1781	
(c) Check here by if you have attached a copy of the attached, the report will be considered incomplete.)	A News - Paess		. (If the notice
Check box for type of annual return ▶ ☑ Form 990-PF	Form 5227	Check this box if your private terminated under section 507	foundation status (b)(1)(A)
Revenues			
1 Amount of gifts, grants, bequests, and contributions receive	ed for the year		5000
2 Gross income for the year			
			69249
Total		, , , , , ,	7+2+93
Dishurramente and			
Disbursements and	and the state of t		
4 Disbursements for the year for exempt (charitable) purpose	es (including administra	ative expenses)	6907159
Expenses attributable to gross income (item 2 above) for	the was		126636
Foundation Man	nagers		
List all managers of the foundation (see section 4946(b)):			
Name and title	Addre	iss where manager may be con- during normal business hours	tected
ROBERT L KROC - PRESIDENT	-		
A		ANTA YNEE, CA 984 LA JOLLA DR. #20	
John & KAOC - VICE PRESIDENT	14 John C		• •
fato L Turner Yest Paracutat		I CARPORATION	
		: Padza. DAKEROOK	
LORRAINE E GRON TREASURER		O. MINZ REDDINGTON	
BALLARD F SMITH - SECRETARY	Po Nos 2000	Jan D. 600 (4 12	12.0
GA HOFFMAN ASSISTANT SECRETARY		A JOLLA DR. 4 do.	
	CA JOLLA CA	92037	-
Wagn lawin - Assistant Strations		HUTH YNEE CH 934	۵.
List here any managers of the foundation who have			
List here any managers of the foundation who have cont dation before the close of any tax year (but only if they h	nave contributed more	or the total contributions than \$5,000). (See section	received by the f 507(d)(2).)
RAY A KAOC			
	r more of the steek -f	A corporation for an are "	
List here any managers of the foundation who own 100/	indation has a 10% of	a corporation (or an equal) r greater interest.	y large portion of
b List here any managers of the foundation who own 10% or ownership of a partnership or other entity) of which the foundation			
of a partite sing of other entity) of which the fou	,		
b List here any managers of the foundation who own 10% or ownership of a partnership or other entity) of which the foundation who own 10% or ownership of a partnership or other entity) of which the foundation who own 10% or ownership of a partnership or other entity) of which the foundation who own 10% or ownership of a partnership or other entity) of which the foundation who own 10% or ownership or other entity) of which the foundation who own 10% or ownership or other entity) of which the foundation who own 10% or ownership or other entity) of which the foundation who own 10% or ownership or other entity) of which the foundation who own 10% or ownership or other entity) of which the foundation who ownership or other entity) of which the foundation who ownership or other entity) of which the foundation who ownership or other entity) of which the foundation who ownership or other entity) of which the foundation who ownership or other entity) of which the foundation who ownership or other entity) of which the foundation who ownership or other entity) of which the foundation who ownership or other entity or ownership or other entity).	,		
of a partite sing of other entity) of which the fou	,		
of a partite sing of other entity) of which the fou	•		

	Balanco.	Shoot For Books	of the Beginning	d the Year	19. The second s
Access.					l l
Com Gree Cal To	Buns Accepted	2.637.8	Accounts payable .		26317
Accounts and notes receiv	reble	138558	Contributions, gifts		
Imentaries			Bonds and notes p	syable	
Securities:			Mortgages payable		
Government obligations					
Corporate bonds			Other liabilities		107126
Corporate stocks		50 177 497	Total liabilities	• • • • • •	/36410
Mortgage loons				Worth	
		***************************************	Principal fund	• • • • • •	7.619359
Real estate	••••••••••			••••••	***************************************
Less: Depreciation .			Income fund		(1131-331)
Other assets	86795		***************************************	•••••••••••••••••••••••••••••••••••••••	••••••
Less: Depreciation .	3632.	J. 475	Total net worth .	•	523.7.28
Total assets	A CONTRACTOR OF THE PROPERTY O	52445238	Total liabilities and		52445288
Itemized		ocurities and All Ot	her Assets Held at	the Close of the Ta	x Year
		4		Ocet velue	Market value
CASH (INCLUSIO	10 CDS. BAN	KERS ACCEPT. Y	Cash Reserves)	3184298	3,16291
RECEITABLES				14.65	14065
FIXED ASSETS.	we r			43426	40426
INVESTMENTS IN	: Goreram	ENT OBLIGATION	ons . Sen 2	1723.88	1658 +50
	CORPORAT	e Bonds . Sc	. 2	1528125	2395775
	CORPORATO	e Stocks . Je	n 2	3716974.	41.11475
					·
			į		
otal				46364742	49379419

Grants and Contributions Paid During the Year or Approved for Future Payment Recipient Name and address (home or business) Paid during year SCHEDULE 4717016 4717016 Approved for future payment * * * * * * * ------4717-16 natice has been published that this Angual Report is available for public inspection at the principal offices of the foundation, and copies of the national Report have been jumpled to the Attoyley General (or his/her designate) of each State entitled to receive reports as required by instruction Mehal Messinger 5/5/11

Date

Instructions

A. Who Must File.—An annual report is required from the foundation managers (as defined in section 4946(b)) of every organization that is a private foundation, including a nonexempt charitable trust de-scribed in section 4947(a)(1) that is treated as a private foundation, and that bas at least \$5,000 of assets at any time during a tax year. A private foundation may file this form as its annual report.

spature of foundation manager

Foundation managers who prefer not to use this form may prepare the report in printed, typewritten, or other form as long as it readily and legibly discloses the information required by section 6056 and the

related regulations.

The annual report is required in addition to, and not in place of, the information required on Form 990-PF under section 6033.

- B. Where and When to File.—File the annual report by the due date of the organization's annual information return, Form 990-PF or Form 5227, with the same service center where the return is filed. See the instructions for Form 990-PF and Form 5227 for more information.
- C. Public Inspection of Private Foundation's Annual Report.-Foundation managers must make the annual report available for inspection during regular business hours at the principal office of the foundation, or may furnish a free copy to any person requesting inspection, provided the request is made at the time and in the man-ner prescribed in section 6104(d) and the related regulations.

A notice that the private foundation's annual report is available for inspection must be published by the due date for filing the annual report, including any extensions of time for filing. The notice must be published in a newspaper with general circulacion in the county in which the principal of-fice of the private foundation is located. (A newspaper or journal that publishes real

estate title transfers or other similar legal notices to satisfy State statutory require-ments is also considered to have general circulation.) The notice must state that the annual report of the private foundation is available for inspection at its principal of-fice during regular business hours by any citizen who requests inspection within 180 days after the date the notice is published. It must also show the address of the pri-It must also show the address of the private foundation's principal office and the name of its principal manager. A private foundation may designate, in addition to its principal office, any other location at which its annual report will be made available. Another location may also be designated if the foundation has no principal office, or none other than the residence of a substantial contributor or foundation manager.

A copy of the notice must be attached to the annual report filed with the Internal Revenue Service. Because IRS makes the annual report available for public inspec-tion under section 6104(d), the report and any attachments should be of such quality that they can be reproduced photographically.

A private foundation that has terminated its status as such under section 507 (b)(1)(A), by distributing all its net assets to one or more public charities without re-taining any right, title, or interest in those assets, should check the box on page 2 indicating termination. It does not have to publish notice of availability of its annual report or furnish the report to the public for the tax year in which it terminates (Reg. 1.507-2(a)(6)).

D. Signature and Verification.—The report must be signed by the foundation

E. Furnishing of Copies to State Officers; isting of States.—Section 6056 requires foundation managers to furnish a copy of the annual report to the Attorney General (or his or her designate) of (1) each State required to be listed in Part V of Form

990-PF or Part III of Form 5227, (2) the State in which the principal office of the foundation is located, (3) the State in foundation is located, (3) the State in which the foundation was incorporated or organized, and (4) any other State if requested. The report must be furnished at the same time it is sent to IRS. The foundation manager must attach to the report a copy of the Form 990-PF (or Form 5227) and a copy of any Form 4720 filed by the foundation with IRS for the year.

F. Penalty for Not Filing the Annual Report and Notice on Time.—If a private foundation does not file the annual report by the due date or does not comply with

13-2692124

Sew Diese Cd 92121

fond Hickman Gads . Massidera Heers INC

Juste 1200

ina d dineer. Preparer's address

> by the due date or does not comply with the requirements under instruction C, the person required to file will be charged a \$10 penalty under section 6652 for each day the report and notice are late, up to a maximum of \$5,000. If more than one person is required to file, all such persons will be jointly and separately liable for the penalty.

The penalty of \$10 a day may also be charged if a report is filed with information omitted. An entry should be made in each part of the form. If a part or line item does not apply, "N/A" (not applicable) should be entered in that space. (See Rev. Nul. 77–162, 1977–1 C.B. 400, for details.)

If the failure to file the annual report or comply with instruction C is willful, a pen-alty of \$1,000 for each such report or notice will be charged in addition to the above

amount. (See section 6685.)
Organizations that have given notice under section 508(b) regarding their foundation status and have not received a determination letter from IRS on their status should refer to Rev. Proc. 79-8, 1979-1 C.B. 487, or later revisions for rules relating to relief from the penalty provision of section 6652.

G. Foreign Organizations.organization which received substantially all of its support (other than gross invest-ment income) from sources outside the United States will not be subject to the re-quiroments of instructions C and E above.

In the Superior Court of the State of California In and for the County of Santa Barbara

746	PEGG EVENDATION
	KROC FUUNDATION
DIRE	IC NOTICE
•	PROOF OF PUBLIC
•	(2015.5 C.C.P.)
STATE OF CALIFORNIA County of Santa Barbara	
eighteen years, and r at a party to clerk of the printer of the Santa Bi and published daily in the City of S has been adjudged a newspaper of a Barbara, State of California, under herein mentioned was set in type no black-face type not smaller than nor the notice intended to be given; the published in each regular issue of sa	s and a resident of the County aforesaid; I am over the age of or interested in the above entitled matter. I am the principal arbara News-Press, a newspaper of general circulation, printerested and serbara, and which newspaper general circulation by the Superior Court of the County of Santar date of June 9, 1952, Case Number 47171; that the notice of smaller than nonparell and was preceded by words printed in parell, describing in general terms the purport and character of at the notice, of which the annexed is a printed copy, has been aid Santa Barbara News-Press on the following dates, to-wit:
all in the year 1981	
I hereby certify (or declare) under	penalty of perjury that the foregoing is true and correct.
Executed this 5th day of M	AV 19 81 at Santa Barbara, CA
0	



Schedule 1 - 12/31/80

Principal Investigator and Institution	Title of Project	Amount
Donald M. Marcus, M.D. Albert Einstein College of Medicine Bronx, NY	Glycosphingolipid antigens of human lymphocyte subpopulations	\$ 19,746
Kevin J. Lafferty, Ph.D. The Australian National University Australia	Human islet transplantation .	16,686
Helen V. Bashir, MB, BS, FRCPA John P. Edmonds, MB, BS, FRACP Andrew F. Geczy, Ph.D., D.Sc. Australian Red Cross Society Australia	Role of environmental agents in the pathogenesis of the seronegative arthropathies: a biochemical study	16,500
Lawrence Chan, M.D. Baylor College of Medicine Houston, TX	Biochemical studies on somatostatin biosynthesis	32,105
Donald M. Marcus, M.D. Baylor College of Medicine Houston, TX	Glycosphingolipid antigens of human lymphocyte subpopulations	23,464
W. Page Faulk, M.D.Blond McIndoe Centre for Transplantation Biology England	Immunological studies of diabetic placenta	27,175
John I. Loewenstein, M.D. Boston University Medical Center Boston, MA	Ocular blood flow in diabetes mellitus	7,065
Neil B. Ruderman, M.D., Ph.D. Boston University School of Medicine (University Hospital) Boston, MA	Polyamine metabolism in diabetes	31,775
Michael P. Czech, M.D. Brown University Providence, RI	Chemistry of the insulin receptor	38,836
Jeremy P. Brockes, Ph.D. California Institute of Technology Pasadena, CA	A pituitary growth factor for cultured rat Schwann cells	39,770

Principal Investigator and Institution	Title of Project	Amount
Alan G. Goodridge, Ph.D. Case Western Reserve University Cleveland, OH	Hormone action in mutant hepatocytes	\$ 22,601
Richard W. Hanson, Ph.D. Case Western Reserve University Cleveland, OH	Role of insulin in the regulation of enzyme synthesis	19,490
Irving Kushner, M.D. Case Western Reserve University Cleveland, OH	Regulation of biosynthesis of murine amyloid-associated proteins	6,462
Charles J. Malemud, Ph.D. Roland W. Moskowitz, M.D. Victor M. Goldberg, M.D. Case Western Reserve University Cleveland, OH	Studies of human cartilage growth and metabolism in aging and osteoarthritis	16,566
Harvey C. Gonick, M.D. Cedars-Sinai Medical Center Los Angeles, CA	Role of chromium deficiency as a cause of diabetes	39,400
James R. Klinenberg, M.D. Cedars-Sinai Medical Center Los Angeles, CA	A double blind controlled study of therapeutic lymphoplasmapheresis in rheumatoid arthritis	14,774
John J. Miller, III, M.D., Ph.D. Children's Hospital at Stanford Palo Alto, CA	Pole of antigen-antibody complexes in juvenile rheumatoid arthritis	27,617
Howard L. Weiner, M.D. Children's Hospital Medical Center Boston, MA	Natural killer cell activity in patients with multiple sclerosis and the relationship between human natural killer cells and measles virus	_7 , 738
Jack R. Battisto, Ph.D. Cleveland Clinic Foundation Cleveland, OH	Studies on the altered IgG human rheumatoid arthritis and development of a mouse model for adjuvant arthritis	36,960
Randall S. Krakauer, M.D. Cleveland Clinic Foundation Cleveland, OH	Investigation in suppressor cells and adaptive immunotherapy in autoimmunity	32,721
Peter C. Dowling, M.D. Stuart Cook, M.D. College of Medicine and Dentistry of New Jersey Newark, NJ	Lyme agent associated joint and nervous system disease on Cuttyhunk Island	11,000

Principal Investigator and Institution	Title of Project	Amount
John W. Prineas, M.D. College of Medicine and Dentistry of New Jersey Newark, NJ	Characterization of virus-like particles and demyelination in acute lesion in multiple sclerosis	\$ -0-
William V. Lumb, D.V.M., Ph.D. Colorado State University Fort Collins, CO	Kinetic analysis of cholesterol and bile acid metabolism after portacaval shunt in Yucatan swine	11,000
Eugene L. Pautler, Ph.D. Colorado State University Fort Collins, CO	Transport of glucose and amino acids across the blood-retinal barrier in streptozotocin-induced diabetic rats	7,986
Eugene L. Pautler, Ph.D. Colorado State University Fort Collins, CO	Glucose and amino acid transport in ocular tissues of dystrophic and diabetic rats	-0-
Pobert W. Phillips, D.V.M., Ph.D. Colorado State University Fort Collins, CO	Yucatan miniature swine as a model for diabetes mellitus	100,148
Isidore Edelman, M.D. Columbia University College of Physicians and Surgeons New York, NY	Use of glucocorticoid analogs to characterize glucocorticoid receptors	34,090
Max J. Appel, D.V.M., Ph.D. James A. Baker Institute for Animal Health New York State College of Veterinary Medicine Cornell University Ithaca, NY	Canine viruses and multiple sclerosis	9,804
George Lust, Ph.D. James A. Baker Institute for Animal Health New York State College of Veterinary Medicine Cornell University Ithaca, NY	Canine hip dysplasia: a model for study of early events in osteoarthritis	39,617
Dolph O. Adams, M.D., Ph.D. Duke University Medical Center Durham, NC	Cytolytic proteases from mononuclear phagocytes in rheumatoid arthritis: effects on connective tissue cells and their regulation	12,530
Sergio L. Abreu, Ph.D. Fordham University Bronx, NY	Effects of interferon on experimental allergic encephalomyelitis and adjuvant arthritis	7,953

Principal Investigator and Institution	Title of Project	Amount
G. D. Aurbach, M.D. Edward M. Brown, M.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Electrical potential of parathyroid cells in response to secretagogues and extracellular calcium	\$ 3,256
Samuel W. Cushman, Ph.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Mechanism of insulin's stimulatory action on glucose transport in the isolated adipose cell	7,980
Monique E. Dubois-Dalcq, M.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Culturing of large quantities of rat Schwann cells and study of their ability to myelinate or remyelinate axons in the central and peripheral nervous system	13,005
C. Ronald Kahn, M.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Study of the metabolism, biochemical and structural characteristics of the insulin receptor in 3T3-L1 fatty fibroblasts	15,200
Ioretta Leive, Ph.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Phagocytosis of bacteria by macrophages: role of the polysaccharide of lipopoly- saccharide in interacting with macrophages and complement	5,000
Harvey B. Pollard, M.D., Ph.D. Foundation for Advanced Education in the Sciences Bethesda, MD	Molecular basis of insulin secretion from pancreatic islet B cells	7,500
Matthew M. Rechler, M.D. Foundation for Advanced Educasion in the Sciences Bethesda, MD	Structure and biosynthesis of an insulin- like growth factor: multiplication stimulating activity	27,457
Harry Keen, M.D., F.R.C.P. Guy's Hospital Medical School England	Metabolic normalization and microvascular disease	23,789
George A. Bray, M.D. Los Angeles County Harbor- UCLA Medical Center Torrance, CA	Hypothalamic peptides in diabetes and obesity	22,212
David W. Hollister, M.D. Los Angeles County Harbor- UCLA Medical Center Torrance, CA	The collagens of normal and osteoarthritic cartilage	42,141

Principal Investigator and Institution	Title of Project	<u>Amount</u>
David L. Rimoin, M.D., Ph.D. Los Angeles County Harbor- UCLA Medical Center Torrance, CA	The genetic heterogeneity of insulin dependent diabetes mellitus	\$ 39,641
Alfred L. Goldberg, M.D. Harvard Medical School Boston, MA	The rapid degradation of insulin and other hormones in bacterial cells	18,448
John W. Angers, M.D. Human Immunology Foundation New York, NY	A diagnostic test for MS	•
Alvin H. Sacks, Ph.D. Institute for Medical Research San Jose, CA	Studies of the vascular problems related to diabetes	20,574
Linda C. Cork, D.V.M., Ph.D. Johns Hopkins Hospital Baltimore, MD	Infectious leukoencephalomyelitis of goats, an animal model of demyelinating disease	39,741
Richard T. Johnson, M.D. Johns Hopkins University Baltimore, MD	The pathogenesis of measles encephalitis in Lima, Peru	9,148
M. Daniel Lane, Ph.D. Johns Hopkins University Baltimore, MD	Regulation of the synthesis, processing and turnover of the insulin receptor in the liver cell	16,300
Shirley E. Poduslo, Ph.D. Johns Hopkins Hospital Baltimore, MD	Oligodendroglia: a study of its surface components	31,645
William L. Chick, M.D. Joslin Diabetes Foundation Boston, MA	Studies of pancreatic beta cells in the pathogenesis and treatment of diabetes	49,940
Robert A. Greenwald, M.D. Long Island Jewish-Hillside Medical Center New Hyde Park, NY	Effects of superoxide radical on connective tissues	28,017
Ralph A. Meyer, Jr., Ph.D. Marquette University Milwaukee, WI	X-linked hypophosphatemia (vitamin D-resistant rickets): a mouse model	36,599
Robert B. Colvin, M.D. Massachusetts General Hospital Boston, MA	Suppression of experimental allergic encephalomyelitis by anti-idiotypes	8,247

Principal Investigator		
and Institution	Title of Project	 mount
Henry J. Mankin, M.D. Massachusetts General Hospital Boston, MA	Demonstration of normal and osteo- arthritic chondrocyte heterogeneity using flow-through cytophotometry	\$ 8,191
Richard J. Wurtman, M.D. Massachusetts Institute of Technology Cambridge, MA	Effects of experimental diabetes on transport of hexoses and other substrates across the blood-brain barrier	22,517
John E. Gerich, M.D. Mayo Clinic and Mayo Medical School Rochester, MN	Control of somatostatin secretion in vitro	23,120
Vanda A. Lennon, M.D., Ph.D. Mayo Clinic and Mayo Medical School Rochester, MN	An immunologic approach to brain differentiation and myelinogenesis	47,455
F. John Service, M.D. Mayo Clinic and Mayo Medical School Rochester, MN	Metabolic normalization and microvascular disease	23,213
Thomas A. Huff, M.D. Medical College of Georgia Augusta, GA	The relation of non-enzymatic glycosylation of lens crystallin to cataract formation in diabetes	13,222
Gordon C. Weir, M.D. Medical College of Virginia Richmond, VA	Separation of cell types of the islets of Langerhans	13,808
Richard L. Drake, Ph.D. Medical College of Wisconsin Milwaukee, WI	Insulin's effect on changing levels of pyruvate kinase mRNA	11,000
Daniel J. McCarty, M.D. Medical College of Wisconsin Milwaukee, WI	Turnover of calcium pyrophosphate dihydrate crystal in vivo	25,250
William L. Duax, Ph.D. Medical Foundation of Buffalo Buffalo, NY	Molecular structure and biological activity of insulin I	26,400
Christian Schwabe, Ph.D. Medical University of South Carolina Charleston, SC	A novel osteoarthritis model	17,341
Gabriel Virella, M.D., Ph.D. Med. al University of South Carolina Charleston, SC	Detection, isolation and characterization of circulating immune complexes in diabetic patients	31,720
•	-6-	

Principal Investigator and Institution	Title of Project	 mount
David Hamerman, M.D. Montefiore Hospital and Medical Center Bronx, NY	A possible viral agent in rheumatoid arthritis: effects on glycosminoglycan synthesis by synovial cells	\$ 11,000
Dugene W. Straus, M.D. Montefiore Hospital and Medical Center Bronx, NY	Studies of the content and kinetics of CCK converting enzymes in obese rodent brains	14,438
Edward C. Franklin, M.D. New York University Medical Center New York, NY	Possible mechanisms for disordered immune regulation in rheumatoid arthritis and related diseases	16,140
Ira M. Goldstein, M.D. New York University Medical Center New York, NY	Oxygen-derived free radicals and inflam- mation	24, 750
Mauro C. Dal Canto, M.D. Northwestern University Chicago, IL	Primary demelination produced by ts mutants of viruses: morphologic, immunohistochemical, immunological and virological studies	35,607
Norbert Freinkel, M.D. Northwestern University Chicago, IL	Effects of pregnancy on intermediary metabolism and diabetes	-0-
Howard L. Lipton, M.D. Northwestern University Chicago, IL	Chronic central nervous system infections in mice produced by human enteroviruses	33,984
Steven G. Krakowka, D.V.M., Ph.D. Ohio State University Columbus, OH	Canine distemper virus and multiple sclerosis	31,658
Jerry R. Mendell, M.D. Ohio State University Columbus, OH	Ultrastructural immunocytochemical localization of the P2 protein in peripheral nervous system	17,739
Charles F. Howard, Ph.D. Oregon Regional Primate Research Center Beaverton, OR	Diabetes in nonhuman primates	14,288
Richard L. Stevens, Ph.D. Robert B. Brigham Hospital Boston, MA	Somatomedin and insulin control of proteoglycan biosynthesis in the human chondrocyte	5,500

Principal Investigator and Institution	Title of Project	Amount
Darrell Doyle, Ph.D. Roswell Park Memorial Institute Buffalo, NY	Transfer of the plasma membrane receptor for insulin from hepatocytes to cells not responsive to insulin	\$ 7,325
Eva M. Kohner, M.D., F.R.C.P. Royal Postgraduate Medical School England	Metabolic normalization and microvascular disease	45,413
Floyd A. Davis, M.D. Rush-Presbyterian-St. Luke's Medical Center Chicago, IL	Effects of plasmapheresis on signs and symptoms in MS	40,294
Rodney Langman, Ph.D. The Salk Institute San Diego, CA	Reconstructing immune responsiveness in vitro from characterized cell lines	16,500
Robert P. Metzger, Ph.D. San Diego State University San Diego, CA	Increased concentrations of glycolate in urine and serum of diabetic subjects	-0-
Donald E. McMillan, M.D. Sansum Medical Research Foundation Santa Barbara, CA	Studies of viscosity of diabetic serum	20,075
Willard P. VanderLaan, M.D. U. J. Lewis, Ph.D. Scipps Clinic and Research Foundation La Jolla, CA	Diabetogenic peptides of the arterior pituitary	64,650
John H. Vaughan, M.D. Scripps Clinic and Research Foundation La Jolla, CA	Thoracic duct drainage in rheumatoid arthritis	27,849
John A. Hamilton, Ph.D. Sloan-Kettering Institute New York, NY	An in vitro model of rheumatoid arthritis	14,684
William C. Dement, M.D., Ph.D. Stanford University Stanford, CA	Sleep, diabetes mellitus, and the autonomic nervous system	24,334
Leslie J. Dorfman, M.D. Stanford University Stanford, CA	Clinical neurophysiological studies in multiple sclerosis and related disorders	-0-

Principal Investigator and Institution	Title of Project		mount
Robert T. Wall, M.D. Hunter Little, M.D. Stanford University Stanford, CA	Intensive plasmapheresis in diabetic microangiopathy	\$	11,000
Stephen G. Waxman, M.D., Ph.D. Stanford University Stanford, CA	Studies on neuronal properties in demyelinating disease		37,910
Milton Alter, M.D., Ph.D. Temple University School of Medicine Philadelphia, PA	B cell antigens in Israeli patients with multiple sclerosis		-0-
Ronald A. Pieringer, Ph.D. Temple University School of Medicine Philadephia, PA	The association of galactosyl diacylglycerols with multiple sclerosis		29,226
Donald R. DiBona, Ph.D. University of Alabama in Birmingham Birmingham, AL	Structural correlates of diabetic nephropathy		6,109
Edward J. Miller, Ph.D. University of Alabama in Birmingham Birmingham, AL	Comprehensive evaluation of t II procollagen from cartilagenous cassue		6,079
Caroline S. Pace, Fh.D. University of Alabama in Birmingham Birmingham, AL	Implementation of a new procedure for determining the molecular requirements for insulin release		24,543
Martinez J. Hewlett, Ph.D. University of Arizona Tucson, AZ	Molecular aspects of bunyavirus infection in neural cells		15,906
Robert I. Mishell, M.D. University of California, Berkeley Berkeley, CA	Induction of resistance to the immuno- suppressive effects of glucocortico- steroids by bacterial peptidoglycan		34,966
M. Eric Gershwin, M.D. University of California, Davis Davis, CA	The pathogenesis of avian scleroderma		11,000
Thomas C. Cesario, M.D. University of California, Irvine Orange, CA	Detection of interferon in serum and synovia fluid of patients with rheumatic disease	1	15,014

Principal Investigator and Institution	Title of Project	_ <u>A</u>	mount
Gale A. Granger, Ph.D. Jim Kostergaard, Ph.D. University of California, Irvine Irvine, CA	Demonstration of lymphocyte effector molecules in the tissue destructive lesions of rheumatoid arthritis	\$	22,992
David T. Kingsbury, Ph.D. University of California, Irvine Irvine, CA	Molecular probes for the detection of mycoplasma and chlamydia in rheumatoid arthritis		28,667
Lewis M. Slater, M.D. Univeristy of California, Irvine Irvine, CA	Immunogenetics of human diabetes		40,464
Rodney Bluestone, M.D., F.R.C.P. University of California, Los Angeles	Cellular regulation in hyperuricemic nephropathy		15,265
Josiah Brown, M.D. University of California, Los Angeles	Ontogeny and typing of histocompatibility antigens in human fetuses		14,180
Yi-Han Chang, Ph.D. Carl M. Pearson, M.D. University of California, Los Angeles	Effects of colchicine on functions of polymorphonuclear leukocytes in patients with gout		20,919
George W. Ellison, M.D. University of California, Los Angeles	Drug studies in multiple sclerosis		81,137
John H. Fessler, Ph.D. University of California, Los Angeles	Basement membrane synthesis by blood vessel endothelial and other cells		14,295
Solomon A. Kaplan, M.D. University of California, Los Angeles	Respiratory distress syndrome in infants of diabetic mothers		18,146
Seymour R. Levin, M.D. University of California, Los Angeles	Insulin infusion and white cell ATPases		10,000
Timothy A. Miller, M.D. University of California, Los Angeles	Factors which influence survival of autogenous muscle grafts and muscle regeneration		11,000
Lawrence W. Myers, M.D. University of California, Los Angeles	Immunological studies in multiple sclerosis		- 0-

Principal Investigator and Institution	Title of Project	Amount
Jack G. Stevens, D.V.M., Ph University of California, I Angeles		\$ 12,314
Jack G. Stevens, D.V.M., Ph University of California, I Angeles		12,919
Wallace W. Tourtellotte, M. Ph.D. Hans Link, M.D. University of California, I Angeles	kaotropic reagents	14,300
Marshall R. Urist, M.D. University of California, I Angeles	The mechanism of bony overgrowth in arthritic disease	30,000
Stafford L. Warren, M.D. University of California, I Angeles	Search for an active agent in rheumatoid Los arthritis	44,450
Jack A. Alhadeff, Ph.D. University of California, S Diego	Characterization of altered glycoprotein San metabolism in human diabetes	15,180
Theodore Friedmann, M.D. University of California, S Diego	An approach to the isolation and charac- San terization of the HGPET gene	8,250
David A.Gough, Ph.D. University of California, S Diego	Development of an implantable glucose San sensor	5,000
Gordon H. Sato, Ph.D. University of California, Diego	Growth of normal pancreatic beta cells in culture and the role of insulin in serum-free medium	7,276
J. Edwin Seegmiller, M.D. University of California, Diego	Ochronotic arthritis and other forms of San hereditary degnerative joint diseases	-0-
Nathan J. Zvaifler, M.D. University of California, Diego	Cryoglobulins in the rheumatic diseases San	-0-
Allen I. Arieff, M.D. University of California, Francisco	Lactic acidosis: effects of therapy San	34,109

Principal Investigator and Institution	Title of Project	Amount
Michael Fischbach, M.D. University of California, San Francisco	Idiotype-anti-idiotype in murine lupus using monoclonal hybridoma induced anti-DNA antibodies	\$ 24,750
Ira M. Goldstein, M.D. University of California, San Francisco	Oxygen-derived free radicals and inflammation	8,627
John Heuser, M.D. University of California, San Francisco	3-D visualization of freeze-dried cells and molecules	33,000
Kenneth P. Johnson, M.D. University of California, San Francisco	Pathogenesis of multiple sclerosis	13,171
Robert R. McKendall, M.D. University of California, San Francisco	Cytotoxicity in multiple sclerosis	8,123
Jackson B. Pickett, M.D. University of California, San Francisco	Effect of insulin on neuromuscular transmission	11,764
William E. Seaman, M.D. University of California, San Francisco	Autoimmunity in androgen resistant EXSB mice	8,227
Marvin D. Siperstein, M.D., Ph.D. Kenneth R. Feingold, M.D., Ph.D. Millie H. Wiley, Ph.D. University of California, San Francisco	Derangement of cholesterol metabolism	39,548
Barry G. W. Arnason, M.D. University of Chicago Chicago, IL	Nonsense antibodies in CSF in multiple sclerosis	20,454
Arthur H. Rubenstein, M.D. University of Chicago Chicago, IL	Metabolic normalization and microvascular disease	19,996
Carol M. Brownscheidle, Ph.D. University of Cincinnati Cincinnati, OH	The spontaneously diabetic BB rat: an animal model for the study of the effects of maternal diabetes mellitus on pregnancy, fetal maturation and neonatal health	7,840
Jerome H. Herman, M.D. University of Cincinnati Cincinnati, OH	Evaluation of mechanisms modulating the activation and release of chondrocyte proteinase activity	21,344

Principal Investivator and Institution	Title of Project	Amount
Jack S. Burks, M.D. University of Colorado Health Sciences Center Denver, CO	Transmission studies in multiple sclerosis	\$ 113,030
Henry N. Claman, M.D. University of Colorado Health Sciences Center Denver, CO	Immunologic responses to insulin	26,643
John S. Goff, M.D. University of Colorado Health Sciences Center Denver, CO	Investigation of diabetic diarrhea	9,900
Sylvia J. Kerr, Ph.D. University of Colorado Health Denver, CO	Methylation of membrane components and insulin action	16,084
Jerrold M. Olefsky, M.D. University of Colorado Health Sciences Center Denver, CO	Mechanism of insulin resistance in chesity	35,052
John E. Repine, M.D. University of Colorado Health Sciences Center Denver, CO	Killing graft macrophages with hyperoxia may facilitate pancreas transplantation in patients with diabetes mellitus	8,485
David W. Talmage, M.D. University of Colorado Health Sciences Center Denver, CO	The abrogation of immune rejection of endocrine grafts	16,354
Paula Dore-Duffy, Ph.D. University of Connecticut Health Center Farmington, CT	Lymphocyte adherence in multiple sclerosis	27,041
Kathrin A. Krakauer, Ph.D. University of Connecticut Health Center Farmington, CT	Synovial cell endocytosis and intracellular digestion: a study of the contribution of synovium to the turnover of joint constituents	11,409
Steven E. Pfeiffer, Ph.D. University of Connecticut Health Center Farmington, CT	Temperature-sensitive lines of myelinating oligodendroglia and Schwann cells	18,441

Principal Investigator and Institution	Title of Project	Amount
Marvin L. Tanzer, M.D. University of Connecticut Health Center Farmington, CT	The synthesis, assembly and secretion of \$ procollagen: A biochemical and genetic approach	19,128
Laurence S. Braude, M.D. Jose G. Cunha-Vaz, Ph.D. University of Illinois at the Medical Center Chicago, IL	Studies in retrobulbar neuritis and multiple sclerosis	11,000
David L. Camenga, M.D. University of Maryland Baltimore, MD	Canine distemper virus induced demyelination: an animal model for multiple sclerosis	41,177
Arthur A. Like, M.D. University of Massachusetts Worcester, MA	Studies of the spontaneous juvenile diabetic syndrome of the bio breeding laboratory rat	42,591
David S. Howell, M.D. University of Miami Miami, FL	Role of matrix vesicles in chondrocalcinosia	28,916
Duane R. Schultz, Ph.D. University of Miami Miami, FL	homomological and biochemical studies of a polysaccharide in an ant venom (Pseudomyrmex sp.): Its use for rheumatoid arthritis	28,438
Jack L. Kostyo, Ph.D. University of Michigan	Growth hormone: structure-function relationships	32,450
Thomas J. Schnitzer, M.D., Ph.D. University of Michigan Ann Arbor, MI	Pathogenesis of avian reovirus arthritis	13,860
Jose Barbosa, M.D. University of Minnesota Minneapolis, MN	Study of nondiabetic sibs with two or more diabetic siblings	11,000
Steven D. Douglas, M.D. University of Minnesota Minneapolis, MN	Immunology and function of mononuclear phagocytes in rheumatoid arthritis	9,625
T. Z. Csaky, M.D. University of Missouri-Columbia Columbia, MO	Epithelial sugar transport and diabetes mellitus	21,450
Pierre Robitaille, M.D. University of Montreal Canada	Relationship between sterility and sperm specific nuclear antigens in insulin- dependent diabetes	11,000

Ô

Principal Investigator and Institution	Title of Project	Amount
K.G.M.M. Alberti, M.D. University of Newcastle Upon Tyne England	Metabolic normalization and microvascular disease	\$ 5,723
R.Philip Eaton, M.D. University of New Mexico Albuquerque, NM	Glucose homeostasis in normal man, obesity and diabetes	-0-
R. Philip Eaton, M.D. William J. Spencer, Ph.D. University of New Mexico Albuquerque, NM	Bioengineering and biomedical development of a programmable/implantable insulin delivery system	38,813
Ralph C. Williams, Jr., M.D. University of New Mexico Albuquerque, NM	Projects related to immune mechanisms in the connective tissue diseases	28,700
Wesley W. Bullock, Ph.D. University of Oregon Health Sciences Center Portland, OR	Regulation of human neutrophils by monosaccharide-inhibitable lymphocyte signals	8,280
Steven D. Douglas, M.D. University of Pennsylvania Philadelphia, PA	Immunology and function of mononuclear phagocytes in rheumatoid arthritis	19,250
Kathrin A. Krakauer, Ph.D. Univeristy of Pennsylvania Philadelphia, PA	Synovial cell endocytosis and intracellular digestion: a study of the contribution of synovium to the turnover of joint constituents	6,826
H. Ralph Schumacher, Jr., M.D. University of Pennsylvania Philadelphia, PA	Articular chondrocalcinosis: factors in crystal deposition	-0-
Donald H. Silberberg, M.D. University of Pennsylvania Philadelphia, PA	Role of alpha-fetoprotein in modifying in vitro CNS demyelination	9,188
Robert Ader, Ph.D. Nicholas Cohen, Ph.D. University of Rochester Aochester, NY	Behavioral processes in the immuno- pharmacotherapy of autoimmune disease	8,227
Glenn L. Wilson, Ph.D. University of South Alabama Mobile, AL	The role of N-nitroso compounds in insulin-dependent diabetes mellitus	5,869

Principal Investigator and Institution	Title of Project	1	Amounc
M. Michael Appleman, Ph.D. University of Southern California Los Angeles, CA	Regulatory mechanisms for lymphocyte activities	\$	10,010
Karl Folkers, Ph.D. University of Texas at Austin Austin, TX	Synthesis of interferon and fragments		28,036
Karl Folkers, Ph.D. University of Texas at Austin Austin, TX	Cooperative research on the synthesis of peptides related to the human growth hormone and having diabetogenic activity		63,649
Grady F. Saunders, Ph.D. University of Texas System Cancer Center Houston, TX	Biosynthesis of glucagon		7,958
Peter Stastny, M.D. University of Texas Health Science Center Dallas, TX	HLA and the immune response in man; predisposition for rheumatoid arthritis		18,150
Donald H. Nelson, M.D. Univerisity of Utah Salt Lake City, UT	Study of the mechanisms by which corticosteroids produce their harmful effects when used in the treatment of arthritis		-0-
Donald H. Nelson, M.D. University of Utah Salt Lake City, UT	Relation of insulin effects on phospholipid metabolism to the increased incidence of cardiovascular disease in diabetes mellitus		16,468
John R. Ward, M.D. University of Utah Salt Lake City, UT	Etiology of human rheumatoid arthritis		-0-
Edward S. Horton, M.D. University of Vermont Burlington, VT	Effects of exercise on insulin resistance in muscle		12,636
Glenn L. Wilson, Ph.D. University of Vermont Burlington, VT	The role of N-nitroso compounds in insulin-dependent diabetes mellitus		11,000
Alan D. Rogol, M.D., Ph.D. University of Virginia Charlottesville, VA	Isolation and purification of a low molecular weight insulin antagonistic peptide from bovine pituitaries		4,981
William P. Arend, M.D. University of Washington Seattle, WA	Neutral protease secretion in human monocytes and macrophages		28,680

Principal Investigator and Institution	Title of Project	A	mount
John W. Ensinck, M.D. University of Washington Seattle, WA	Glucose 'control' in diabetic humans using a glucose controlled insulin infusion system	\$	14,455
Wilfred Y. Fujimoto, M.D. University of Washington Seattle, WA	Epidemiology of maturity-onset type diabetes and its morbid consequences		8,004
Daniel Porte, Jr., M.D. University of Washington Seattle, WA	The role of pancreatic islet cell electrical activity in glucose-induced insulin release		7,774
R. Paul Robertson, M.D. University of Washington Seattle, WA	Regulation of prostaglandin E receptors in pancreatic islet plasma membranes		14,458
Robert H. Williams, M.D. University of Washington Seattle, WA	Investigation pertinent to collagen changes in some common disorders		-0-
John Dupre, M.D. University of Western Ontario Canada	Metabolic normalization and microvascular disease		19,939
Thomas H. Steele, M.D. University of Wisconsin Madison, WI	Renal urate handling: relationships between hypertension, hyperuricemia, and the pathogenesis of gout		27,880
G. Guy Dodson, Ph.D. University of York England	Molecular structure and biological activity of insulin II		35,640
Claes Hellerstrom, M.D., Ph.D. Uppsala Universitet Sweden	Transplantation of fetal pancreas to diabetic patients		8,206
Raymond L. Woosley, M.D., Ph.D. Vanderbilt University Nashville, TN	Drug-induced lupus erythematosus: investigation of the role of reactive metabolites		15,800
Travis C. McGuire, D.V.M., Ph.D. Washington State University Pullman, WA	Studies on caprine arthritis- encephalitis		7,500
John Heuser, M.D. Washington University St. Louis, MO	3-D visualization of freeze-dried cells and molecules		17,345
Paul E. Lacy, M.D., Ph.D. Washington University St. Louis, MO	Allografts of isolated islets of Langerhans		82,667

Principal Investigator and Institution	Title of Project	_1	Mount.
David W. Scharp, M.D. Washington University St. Iouis, MO	Isolation and culture of islets for transplantation	\$	75,723
David W. Scharp, M.D. Paul E. Lacy, M.D., Ph.D. Washington University St. Louis, MO	Studies on the isolation and transplan- tation of fetal pig islet tissue		19,250
Benjamin D. Schwartz, M.D., Ph.D. Washington University St. Louis, MO	A biochenica ¹ approach to study the relationship between HLA antigens and arthritic diseases		16,816
John L. Trotter, M.D. Washington University St. Louis, MO	Immunosuppression in multiple sclerosis		30,933
Margo P. Cohen, M.D. Wayne State University Detroit, MI	Cultured retinal microvessel cells: a model for study of diabetic retinopathy		15,116
F. Arthur McMorris, Ph.D. The Wistar Institute Philadelphia, PA	Effect of viruses on myelin functions in vitro		8,350
John Hooss, M.D. Yale University New Haven, CT	Immunosuppression of B cell function in multiple sclerosis		24,512
Philip Felig M.D. Yale University New Haven, CT	The metabolic response to exercise in normal and diabetic humans		49,908
Stephen E. Malawista, M.D. Yale University New Haven, CT	Clinical and laboratory studies of arthritis		-0-
Pobert S. Sherwin, M.D. Yale University New Haven, CT	Metabolic normalization and microvascular disease		35,953
Joan A. Steitz, Ph.D. Yale University New Haven, CT	Structure-function studies of small RNPs precipitated by the lupus antibody La		7,212
Hunter L. Little, M.D. Zweng Memorial Retinal Research Menlo Park, CA	The effect of constant subcutaneous infusion of regular insulin on the course of diabetic retinopathy		11,000

or concernations, orrest, or and	N. W Walket
Schedule 1 - 12/31/80	36-6125258
Paginiant	
Recipient	Amount
Dartmouth Medical School Hanover, New Hampshire	\$ 171,733
Michigan State University East Lansing, Michigan	266,828
Southern California Tissue Society	500
March of Dimes	100
Grant Hospital Library Fund	100
University of Arizona	500
International Society of Endocrinology	1,500
Perspectives in Biology	350
American Diabetes Association - So. Cal. A	Affiliate 225
The Aesculapians	200
Hanot Foundation	10
Visiting Nurse Association	100
Regents of the University of Southern Cali	fornia 100
Reed Neurological Research	500
Arthritis Foundation	100
American Thyroid Association	300
National Multiple Sclerosis Society	100
Eisenhower Medical Center Diabetes Program	1,000
7th Parathyroid Conference	500
American Diabetes Association	125
National Multiple Sclerosis - N.Y. Chapter	200
Stanford University School of Medicine	100,000
Research to Prevent Blindness	100
Foundation Center	2,500
Alzheimers Disease	100
Western Association of Physicians	1,000
Family Renewal Center, Fairview - Southdal	e Hospital 10,000
Aloha House	2,000
United Way	10
TOTAL CONTRIBUTIONS, GIFTS,	GRANTS \$ 4,787,086

Kroc Foundation

Schedule of Contributions, Gifts, Grants

All grants are for medical/scientific research. No recipient is related to The Kroc Foundation in any way.

. 0

Service Services

ATEMENT NO. 2 (99. 42)						CONTRACTOR NO	11-11-1		12/01/	
SCHEDULE OF MARKET ABLE SECURITIES	# Su 11	m,	c,	JF			AKET LUE			
GOVERNMENT DALIGATIONS:										
US TREASURY NOTE	3			49 9	-45		507	2		
FEBERAL NATE MORTGHEE ASSN	50.	• • •		41.	156		465			
FEDERAL NAIL MORIGAGE ASSN	25-			2 + +	611		232	5		
PROCEAL FARIN CHEDIT BANKS	500			¥ 7 7	219		453	750		
			,	723	.11		650	450		
CORPORATE BONDS:										-
AMERICAN MEDICAL IVIL CUDER	165	•••		168	•••		249	ADMINISTRATION		
Buile CASCAGE BOND	5	•••		5			+19	3 55		
dicital Equip CV Dea	2	•••		24.	• ••		267	SHIP OF SHIP		
FLORIDA POWER + LIGHT 1ST MIGIBOUR	500	000		471	-	market and the contract of	413	-		
CMAC DIA				795	-	- Commence	445	Constitution behavior for	-	
HERCULES INC NOTE	500			475	-	A STATE OF THE PARTY OF THE PAR	45.0	Complex Communities		Name of Street, Street
INTL MINERAL & CHAIR HIL BOND		000		495			445	-		
LONE STAR MOUSTRIES CES		•••		5			457	an - James Com		
MANCO CV DIB	200			?			222	•••		
		-								
			3	521	125	j	195	775		
ORPORALE STUCKS:		-								
ATLANTIC RICHFIELD		•••		19.	Section through		19.	200000000000000000000000000000000000000		
Canoco ING		•••			311		172			
Dun BANGSIREET COAP					410		215	-		
FLORAL ENRIS				1 87	a contraction of		354	-		-
GENERAL ELLETRIC		5			333	Manhaman Libert	334	-		
HALLI AVAION		•••			747	CHARLES CONTRACTOR	351	-		-
HEWELT IGENORE		250			747		204	-		-
Hoseige Coar of America	1						*************	875		
HUGHES TOOL CO		•••			259		2.3	Annual Section		-
, 37		6			110		249	-		-
Jonniew & Jonnie				30,000	**		364	1		
Littou /NOUSTRIES					٤		35,			
SCHLUMBERGER LID		• • •			. "		397	-		Personne
STANDARA OLL MAIRWA		• • •			5.3		211	-		
Jignoneo One On.					110	-	341	1		-
Texas lustruments Times Middon		000		115	1		249	-		
		319			•••		¥ 2 5			
WANG LABORATERIES					140		3.0			
WARNER COMMUNICATIONS WELTERN BANCORPORATION		•••			5		216	-		
STEIN ROL . FARNAM GP OF FUND					• • •		26.			
STEIN ROE SPECIAL FUND		. 7 1			112	-	3.7			
STEIN ROE UNIVERSE FUND INC	-	,,,			31.		316	Section of the second		-
M. DONALOS CORPORATION		• • •		-64			125	-		
· · · · · · · · · · · · · · · · · · ·								-		
		1			710	41	-			_

11.1583EM

Return of Private Foundation Exempt from Income Tax

1980

Please type, print, or attach label. See Specific Instructions of the Control of	For the calendar		r section but(c)(3) of the li		this ten a serious conduction that the product a tool as a serious as	. 19
Please type, print, or attach label. See Specific Instruction See Specific Instruction If address changed, check here \(\) \\ \(\) \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	Committee to the section of the sections	The second secon		1980 and endir	The second secon	and the second s
print, or attach label. See Specific Instructions If address changed, check here >	Please type,		990PF 12 4	0- 03		
See Specific Instructions The address changed, check here		KROC FOUNDATIO	N	11	THE RESIDENCE OF THE PARTY OF T	the same of the sa
See Specific Instructions City 1919 Years to Young to Young the Adverse Survey to Surv	attach label.	Addr % G. A HOFFMAN	T.C.	Ď		
Instructions Comparison C	See Specific		€ ★	22100 1		
Foreign organizations, check here	Instructions	1	A DRIVE. Suite 2		Fair market value of	essets at end of
The books are in care of \$ \frac{1}{2} \fr		LA JOLLA CA S	72.37	- 1	Year	
Income I	If address chang	ed, check here 🕨 🗹	Foreign organizations,	check here	47379 48	9
Income I	The books are in car	e of - FORD. HICKMAN. GIANS	+ MASSINGER . ACCOUNT	ANIS . We.	If exemption application	on is pend-
1 Gross contributions, gits, grants, etc. (see instructions) 2 Contributions from split-interest projects (see instructions) 3 Gross dues and assessments 6 Gross rents and royalties 7 Net gain or (loss) from sale of assets not or time 11 1/2 Contributions from split from any business activities: (Gross receipts ▶ \$ minus cost of sales ▶ \$ minus cost of	Located at > 600	8 ST #1200 SAN DIEGO CA 9	2 , Telephone no. >	231-0331		
1 Gross contributions, gifts, grants, etc. (see instructions) 2 Contributions from split-interesty must (see instructions) 3 Gross dues and assessments 6 Gross rents and royalties 5 Dividends 6 Gross rents and royalties 7 Net gain or (loss) from saie of assets not ording 17 Mode 8 Capital main net income (see instructions) 9 Net short-term capital gain (see instructions) 10 Income modifications (see instructions) 11 Gross profit from any business activities: (Gross receipts \$ minus cost of sales \$ \$) (see instructions) 12 Other income (attach schedule) 7 / 7 / 7 7 / 7 / 7 / 7 / 7 / 7 / 7			S (A) Revenue and			(D) Disbursements
2 Contributions from split interest jouts (see instructions) 4 Interest 5 Dividends 7 Net gain or (loss) from saie of assets not on line 11 1/1/2 8 Capital min net income (see instructions) 9 Net short-term capital gain (see instructions) 10 Income modifications (see instructions) 11 Gross profit from any business activities: (Gross receipts \$ minus cost of sales \$ \$	(Se	e instructions for Part 1)				
2 Contributions from split interest jouts (see instructions) 4 Interest 5 Dividends 7 Net gain or (loss) from saie of assets not on line 11 1/1/2 8 Capital min net income (see instructions) 9 Net short-term capital gain (see instructions) 10 Income modifications (see instructions) 11 Gross profit from any business activities: (Gross receipts \$ minus cost of sales \$ \$	1. Gross con	tributions, gifts, grants, etc. (see jostru	(ms) . 50000			
A Interest 5 Dividends 6 Gross rents and royalties 7 Net gain or (loss) from saie of assets not of line 11. (C.) 8 Capital ain net income (see instructions) 10 Income modifications (see instructions) 11 Gross profit from any business activities: (Gross receipts > \$ minus cost of sales > \$) (see instructions) 12 Other income (attach schedule)						
4 Interest 5 Dividends 6 Gross rents and royalties 7 Net gain or (loss) from sale of assets not of line IT Mog 8 Capital main net income (see instructions) 10 Income modifications (see instructions) 11 Gross profit from any business activities: (Gross receipts > \$ minus cost of sales > \$ (Gross receipts > \$ minus cost of sales > \$ (Gross receipts > \$ minus cost of sales > \$ (Gross receipts > \$ minus cost of sales > \$ (Gross receipts > \$ minus cost of sales > \$ (Gross receipts > (.1	UF	ENTED			***************************************
5 Dividends 6 Gross rents and royalities 7 Net gain or (loss) from saie of assets not or kine 11 1/05 8 Capital rain net income (see instructions) 9 Net short-term capital gain (see instructions) 10 Income modifications (see instructions) 11 Gross profit from any business activities: (Gross receipts > 5	1	17Fp 400	9 36/000	361000	361000	
6 Gross rents and royalties 7 Net gain or (loss) from saie of assets not or line 11 // Cp 8 Capital ain net income (see instructions) 10 Income modifications (see instructions) 11 Gross profit from any business activities: (Gross receipts > 5 minus cost of sales > 5 (see instructions) 12 Other income (attach schedule) / / / / / / / / / / / / / / / / / / /	5 Dividend		NO 1016 +11	1016 411	Additional our constraint to be accessed	
7 Net gain or (loss) from sale of assets not or line 11 1/1/CB 8 Capital main net income (see instructions) . 9 Net short-term capital gain (see instructions) . 10 Income modifications (see instructions) . 11 Gross profit from any business activities: (Gross receipts > \$ minus cost of sales > \$) (see instructions) . 12 Other income (attach schedule) \$ 7/7/7 . 13 Total—add lines 1 through 12 . 14 Compensation of officers, etc. (see instructions) . 15 Other salaries and wages . 16 (a) Pension plan contributions (enter number of plans >	6 Gross re	So EAD	374			
9 Net short-term capital gain (see instructions) 10 Income modifications (see instructions) 11 Gross profit from any business activities: (Gross receipts \$	7 Net gain o	. n. 02	AVICO (97+125)			
9 Net short-term capital gain (see instructions) 10 Income modifications (see instructions) 11 Gross profit from any business activities: (Gross receipts \$	8 Capital			12700175		
19 Income modifications (see instructions) 11 Gross profit from any business activities: (Gross receipts \$ minus cost of sales \$ \$	9 Net short		2000		- • -	
11 Gross profit from any business activities: (Gross receipts > \$ minus cost of sales > \$.) (see instructions) 12 Other income (attach schedule) \$\frac{7}{7}\frac{7}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{2}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{2}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{2}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{2}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{2}{2}\frac{4}{2}\frac{2}{2}\frac{2}{2}\frac{2}{2}\frac{4}{2}\frac{2}\frac{2}{2}\frac{2}					4 19	
(Gross receipts ▶ \$ minus cost of sales ▶ \$	1				***************************************	
of sales > \$			1			
12 Other income (attach schedule) \$\frac{777}{13} \tau_{\text{-add lines 1 through 12}} \tau_{\text{-add lines 1 through 23}} \tau_{\text{-add lines 1 through 24}} \tau_{\text{-add lines 1 through 24}} \tau_{\text{-add lines 1 through 24}} \tau_{-add lin	1					
13 Total—add lines 1 through 12	1		-		234677	
14 Compensation of officers, etc. (see instructions) 15 Other salaries and wages				1427995.	1413.38	
15 Other salaries and wages	1	THE PERSON OF TH	The state of the s	12400	12400	49600
16 (a) Pension plan contributions (enter number of plans						Contract to the second contract to the contrac
plans		-	mber of	*****************		************
(b) Other employee benefits					1 1	All S
17 Investment, legal, and other professional services 18 Interest 19 Taxes (see instructions) 20 Directation, amortization, and depletion (see instructions) 21 Rent 22 Other expenses (attach schedule) 23 Contributions, gifts, grants (see instructions) 24 Total—add lines 14 through 23			/0107	2161	2161	8646
18 Interest 19 Taxes (see instructions) 20 D preciation, amortization, and depletion (see instructions) 21 Rent 22 Other expenses (attach schedule) 23 Contributions, gifts, grants (see instructions) 24 Total—add (ines 14 through 23	bia (Services 55578	41684		13894
19 Taxes (see instructions) 20 D preciation, amortization, and depletion (see instructions) 21 Rent 22 Other expenses (attach schedule) 23 Contributions, gifts, grants (see instructions) 24 Total—add lines 14 through 23				*****************		*******
20 D preciation, amortization, and depletion (see instructions) 21 Rent 22 Other expenses (attach schedule) 23 Contributions, gifts, grants (see instructions) 24 Total—add lines 14 through 23	Ω.		304213	25,0	25.0	10031
21 Rent 22 Other expenses (attach schedule) 23 Contributions, gifts, grants (see instructions) 24 Total—add lines 14 through 23				-		
22 Other expenses (attach schedule)	1	m, emortization, and depiction (see ins	indictions/	***************************************		teanteanteantean
23 Contributions, gifts, grants (see instructions) . 4787.16 24 Total—add lines 14 through 23		censes (attach schadule)	1562776	10012	10012	1552964
24 Total—add lines 14 through 23		,			SHIMMAN SHAPE	4717.16
25 (a) Excess of revenue over expenses: Line 13 minus line 24 (b) Net investment income (if negative enter -0-) (c) Adjusted net income (see instructions) (if negative enter -0-) Part II Excise Tax On Investment Income			2110/			6617474
(b) Net investment income (if negative enter -0-) . (c) Adjusted net income (see instructions) (if negative enter -0-) Part II Excise Tax On Investment Income	Ε.	-	and the same of th			
(c) Adjusted net income (see instructions) (if negative enter -0-) Part I Excise Tax On Investment Income			Vinnilianina	14162366		
	, ,		(0.03311.03311.06317.06 3317.0		1415452	
					Charles and the second	
	ELIZABETH CONTROL CONT		THE STATE OF THE S	ter 4% of line 25(h)	213247
2 Credits: (a) Foreign organizations—tax withheld at source with organizations of the 25(b).	2 Credits: (a)	oreign organizations—tax withh	eld at source		1	
(b) Tax paid with application for extension of time to file (Form 2758). Bt NAM. 21719+ 21719+	(b)	ax paid with application for exten	nsion of time to file (Form	758 AL RETURN	217194	287894
3 Tax due—line 1 minus line 2. Pay in full with return. Make check or money order payable to Internal Revenue					-	ALTA DESCRIPTION OF THE PARTY O
Service (write employer identification number on check or money order)				order payable to	Internal Nevertor	
4 Overpayment—line 2 minus line 1.			Ji check of money order)	TATEMENT	7	2647
Foreign organization—Enter book value > \$ and fair market value > \$ of investment assets held in U.			and fair market valu		of investmen	
Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief it	Under penalties	of perjury, I declare that I have examined th	his return, including accompanying so	chedules and statements, a	end to the best of my know	The second section was a second secon
true correct and camplete. Declaration of preparer (other than taxpever) is based on all information of which the preparer has any knowledge.	true correct and	complete. Declaration of preparer (other than	texpayer) is based on all information	of which the properer has	any knowledge.	
Massinger 5/11/3 Nestell Massinger		M/mm	5/11/13	au (Ma	sampa	
Signature of officer of trustee Date Preparer's signature	diameter of a	officer of trustee				.)
TO I FAMA MINISTER IN PROPERTY AND A SECOND	signature o	Λ	Fa. a.	A # . A	AAS WMALL	Manager 1
Signature of officer of trustee Dote Preparer's signature Fig. 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10	200	tat Septen				

194

Form 990-PF (1980

SERVICE PARAMETER SHEVES	Reginning	of tax year	End of	tan yans
Assets	(A) Amount	(B) Yetel	(C) Amount	(O) Total
1 Cook:				
(e) Savings and Interest-bearing accounts (1) Other	4.2.4.4.4.			
2 Accounts receivable net	2767/	24.111	26929	107029
3 Notes receivable net (attach schedule)		****************		**********
4 Inventories		***************		*****************
5 Government obligations:		****************		***************
(a) U.S. and instrumentalities			1723.89	
(b) State, subdivisions of States	****************		****************	1723018
6 Invastments in corporate bonds, etc. (attach schedule)		*******		3528125
7 Investments in corporate stocks (attach schedule) Sch. 3				3786974"
8 Mortgage loans (number of loans >).		**************************************		************
9 Other Investments (attach schedule)		1966195		3077269
10 Depreciable (depletable) assets (attach schedule):				
(a) Held for investment purposes	***************************************			11.
(b) Minus accumulated depreciation				************
(c) Held for charitable purposes Sow. 5 A .	167.23		11721	
'(d) Minus accumulated depreciation	3432.	5.475	45372	43426
11 Land:				
(a) Held for investment purposes				***********
(b) Held for charitable purposes	,	******************		***********
12 Other assets (attach schedule)		153551		14065
13 Total acsets		52445231		46364742
Liabilities				
14 Accounts payable		26384		5 7 73 4
15 Contributions, gifts, grants, payable		******************		***********
16 Mortgages and notes payable (attach schedule)		109126		490480
18 Total liabilities		136 210		349014
Net Worth (Fund Balances)		/36 8 / 6		
19 Principal fund >				
***************************************		70 617 357		49494534
20 Income fund >		***************************************		******************

***************************************	£**	<18310881>		<2367.88.67
21 Total net worth (fund balances)		52309 - 21		46015728
22 Total liabilities and net worth (line 18 plus line 21)		52445211		46364782
Part IV Analysis of Changes in Net Worth				
1 Total net worth at beginning of year-Part III, C	Column B, line 21 .			523.9.28
2 Enter amount from Part I, line 25(a)				<6293300.
3 Other increases not included in line 2 (itemize)		************	**********	
· · · · · · · · · · · · · · · · · · ·		******************	***********	
***************************************			28	

***************************************	**************	**********	************	SACAMON MET CONTRACTOR CONTRACTOR CONTRACTOR CONTRACTOR CONTRACTOR
4 Total of lines 1, 2, and 3				46015728
5 Decreases not included in line 2 (itemize)				
			1	

******************************			*************	
			1	
6 Total net worth at end of year (line 4 minus line 5)—Part III, Cclumn	D, line 21		46015728

-	Pa	Statements Regarding Activities	luse metromonomica	Fings .
-	No f	orm 4720 if you answer "He" to question 10(b), 11(b), or 14(b); or if you session "Yes," to question 10(c), 12(b), 13(a), or 13(b).	Tyes	T No.
	1 (a) During the tax year, did you attempt to influence any national, State, or local legislation?		
	•	b) During the year did you participate or intervene in any political campaign?	1-	1
	4	c) Did you spend more than \$100 during the year (either directly or indirectly) for political purposes (see instructions for definition)?	-	1
		If you answered "Yes" to 1(a), (b), or (c), attach a detailed description of the cutting and	1000	N SERVICE SERVICE
		or any materials published or distributed by the organization in connection with the activities.		
			1	1
		lave you angaged in any activities which have not previously been reported to the Internal Revenue Service?		Y
		"Yes," attach a detailed description of the activities.		
		lave you made any changes, not previously reported to the IRS, in your governing instrument, articles of incorpo-		
		ation, or bylaws, or other similar instruments?		1
		"Yes," attach a conformed copy of the changes.	Per	
-	T !!	a) Did you have unrelated business gross income of \$1,000 or more during the year?		IV
		b) If "Yes," have you filed a tax return on Form 990-T for this year?		
	ol	as there a liquidation, termination, dissolution, or substantial contraction during the year? "Yes," attach a schedule for each asset disposed of showing: the type of asset, the date of disposition, its cost or the type in the type of asset, the date of disposition, its cost or the type of asset, the date of disposition, its cost or the type of asset, the date of disposition, and the name and address of each recipient to whom assets of the type of type of the type of ty		
•	6 (a	Did you have at least \$5,000 in assets at any time during the year?	- Landson	
	4	"Yes," did you file the annual report required by section 6056 (see Form 990-AR for instructions)?	1	-
•	7 A	re the requirements of section 508(e) (relating to governing instruments) untisfied? (See instructions)	1	
	11	"Yes," are the requirements satisfied by:		-
	(4	Language in the governing instrument (original or as amended), or	1	
	(b) Enactment of State legislation that effectively amends the governing instrument with no mandatory directions		0.20000000
		in the governing instrument that conflict with the State law?		1
8	(a) Enter States to which the foundation reports or with which it is registered (see instructions)	2000	WEEKS
	****	CALIFORNIA AND ILLINOIS		
	(b) If you answered 6(a) "Yes," have you furnished a copy of Form 990-AR (or equivalent report) to the Attorney		
		General (or his/her designate) of each State as required by Connect to the state of	William V	
9	Ar		200000	THE REAL PROPERTY.
-		To you claiming status as an operating foundation within the meaning of sections 4942(j)(3) or 4942(j)(6) for colentry year 1980 or fiscal year beginning in 1980 (see instructions for Part XII)?	200000	
10		"Yes," complete Part XII.	2000000	lamina.
-	(8	During the year did you (either directly or indirectly):		
		(1) Engage in the sale or exchange or leasing of property with a disqualified person?		
		(2) Borrow money from, land money to, or otherwise extend credit to (or accept it from) a disqualified person?		5
		(3) Furnish goods, services, or facilities to (or accept them from) a disqualified person?		-
		(4) Pay compensation to or pay or reimburse the expenses of a disqualified person?		-
		(5) Transfer any of your income or assets to a disqualified person for make any of a than available for the	-	<u> </u>
		benefit or use of a disqualified person)? (6) Agree to pay money or property to a government official? (Exception: check "No" if you agreed to make a grant to or to employ the official for a period after he or she terminates government section!		~
٠		grant to or to employ the official for a period after he or she terminates government service if he or she is terminating within 90 days.)		/
	(b)) If you answered "Yes" to any of the questions 10(a)(1) through (6), were the acts you ergaged in excepted acts	determinants	
		as described in the instructions for this line?		
	(c)	Did you engage in a prior year in any of the acts described in 10(a), other than excepted acts, that were acts of	-	-
		self-dealing that were not corrected by the first day of your tax year beginning in 1980?		,
11	Ta	xes on failure to distribute income (section 4942) (does not apply for years you were an operating foundation as	23333332	200000000000000000000000000000000000000
	def	fined in section 4942(j)(3) or 4942(j)(6)):		
		Did you at the end of tax year 1980 have any undistributed income (lines 6(b) and (c), Part YI) for tax year(s)		
		beginning before 1980?	20000	ALIAN.
		If "Yes," list the years	75777775h	
	(b)	If "Yes," to (a) above, are you applying the provisions of section 4942(a)(2) (relating to incorrect valuation	William .	Million,
		of assets) to the undistributed income for ALL such years?		
	(c)	If the provisions of section 4942(a)(2) are being applied to ANY of the years listed in (a) above, list the years	mm	000000
	•	here and see the instructions		
2	Tax	es on excess business holdings (section 4943):	MAAA	WANTA.
	(a)	Did you hold more than 2% direct or indirect into the interest and purposes enterprise at any time during the year?		/
	(p)	it is, did you have excess business holdings in 1980 as a result of any purchase by you or disqualified and	Tändiken eurongen.	- Angle Stripter and reserve to the Stripter Str
	_	or after the lapse of the 10-year first phase holding societ?		
Olicard		or after the lapse of the 10-year first phase holding period?	000000	THE STATE OF THE S

Total number of other employees paid over \$30,000 >

HON E

Minimakinda mana mananananan mananan m	or professional serv	Ces tot 1390	(see Instructions):					
Name and ad	dress of persons pold n	Туре	of service	Compensation				
***	***************	*************	*****	TARRESTERMENT (Anni-markschon) edicinesis va etingistasseren		Tower-one instruments stratigated exhibitoring processor contracting		
***************************************		e	graph for the contract of the	- Million Million and Color and Colo				
	TO THE OFFICE POSSIBLE STOCKED WITH STOCKED STOCKED STOCKED STOCKED STOCKED STOCKED STOCKED STOCKED STOCKED ST							
************************		and a special control and an accompany of a case / a case a case /		MARKET Tradescript the section of th				
***********	**************	***********	*********			With the Confidence of the Confedence of the Con		
I number of others receiv	ing over	Military and the Control of the Cont	oligin minnigh-minigh-dargo taloonistanalar — milit brooksistamaks					
000 for professional ser	vices >							
a. Kind of property, Indi	and Losses for Ta			l o Ham acquired				
real estate, or other	(specify)	100 si 2 stor	ption (examples: h. of "Z" Co., y b./tok, etc.)	e. How acquired P—Purchase D—Denation	d. Date acquired (mo., day, yr.)	e. Date solo (mo., day, yr		
SCHEOULE	4	***************************************	••••••	•••••				
······································	***************************************	***************************************						
***************************************	****************	***********	*************	*******	***************************************	**************		
***************************************	************	************	*****************	***************************************		***************		
*******************	· 中央会社会社会の対象技術のの概要を ************************************	*****************	• • • • • • • • • • • • • • • • • • • •		***********************			
*************	***********	***************		•••••	•••••••			
**************************************		**********			·····	*************		
f. Gross sales price g. Depreciation minus expense of sale (or allowab		allowed bie)	h. Cost or ot	her basis	i. Gain (f plus g	i. Gain or (loss) (f plus g minus h)		
*******************	3 ·	************	*************		*****	** * * * * * 5 5 7 * * 1 4 * 5 * 8 5 *		
************************	·**(Т п ф t) т ф б б б б б б б б б б б б б б б б б б	************	***************************************	**********	·•····	********		
******************	***********************	*******	*****	• • • • • • • • • • • • • • • • • • • •				
************************	**********************	**********	************		************************			
******************	*****		***************************************	*************	********			
******************	***************************************	************			***************************************			
************************		************	****	********	******************			
	***************************************	************	************************	***************	***********	************		
Complete only for assets a	thowing gain in column	i and owned t	by the foundation on	12/31/69	m. Losses	(from cal. i)		
F.M.V. as of 12/31/69	k. Adjusted I se of 12/31	/ 69	i. Excess o over col. k,	of col. , if any	Gains (excess of	col. I gain over co is than zero)		
***************************************	******************	•••••	•••••	****************				
***************************************	*******************	************	***************************************	•••••••	***************************************	••••••		
	*******************	**********	*****************	***************************************	***************************************	************		
************	****************************		***************************************	••••••	*****************			

~	*******************************	••••••		***************************************	******************	**************		
	***************************************	· · · · · · · · · · · · · · · · · · ·			******************			
***************************************	***************				***************************************			
					- Marine and Alexander and Ale			
pital gain net income or ((net capital loss) .	If gain, also	enter in Part I, line er -O- in Part I, lin	8 }	/ 2 4 0	• /75		

Part VIII Minimum Investment Return for 1980 (Operating Foundations—See instructions)

		CONTRACTOR OF THE PROPERTY OF
1 F	air market value of a sets not used (or held for use) directly in carrying out exempt purposes:	
(a) Average monthly fair market value of securities	47 513 933
(b) Average of monthly cash balances	323910
(c) Fair market value of all other assets (see instructions)	57 49.
(d) Total (add lines (a), (b), and (c))	471754.3
2 /	Acquisition in a tredness applicable to line 1 assets	
3 1	Line 1(d) minus line 2	478954-3
	Cash deemed held for charitable activities—enter 1½% of line 3 (for greater amount, see instructions)	7,1431
• (Cash deemed held for chantable activities—enter 172 /6 or mile o (15. 8. enter a mile of the chantable activities	42.21971
-5	Líne 3 minus line 4	23588 +9
6 (Enter 5% of line 5	233777
F	Computation of Distributable Amount for 1980 (See instructions—not applicable to operating foundations)	
1	Adjusted net income from Part I, line 25(c)	148412
		23511 47
2	Minimum investment return from Part VIII, line 6	
3	Enter the larger of line 1 or line 2	2351147
4	Total of:	
-	(a) Tax on investment income for 1980 from Part II, line 1	
	(b) Income tax on unrelated business income for 1980 (Form 990-T)	213247
5	Distributable amount (line 3 minus line 4)	2075602
6	Adjustments to distributable amount (see instructions)	
7	Distributable amount as adjusted (line 5 plus or minus line 6)—also enter in Part XI, line 1	2.756.2
	Part X Qualifying Distributions in 1980 (See instructions)	
1	Amounts paid (including administrative expenses) to accomplish charitable purposes:	
•	(a) Expenses, contributions, gifts, etc.—total from Part I, column (D), line 24	6617494
	(b) Program-related investments (see instructions)	
2	Amounts paid to acquire assets used (or held for use) directly in carrying out charitable, etc., purposes	
3	Amounts set aside for specific projects which are for charitable purposes	
	Total qualifying distributions made in 1980 (add lines 1, 2, and 3)—also enter in Part XI, line 4	66,7494
_		

Part XI Computation of Undistr Income (See instruction		(e) Corpus	(b) Years prior to 1979	(c) 1979	(d) 1980
1 Distributable amount for 1980 from F	Part IX				20756.2
2 Undistributed income, if any, as of the					
(a) Enter amount for 1979				4 -	
(b) Total for prior years:			-	VIII (1800) (1800) (1800)	
3 Excess distributions carryover, if any,					
(a) From 1975	11-1-1				
(b) From 1976	1413484				
(c) From 1977	22-7525				
(d) From 1978	470 3,21		•		
(a) From 1979	46 45.7 2				
(f) Total of 3(a) through (e)	No. of the contract of the con	13765321			
4 Qualifying distributions for 1980 (AND THE RESIDENCE OF THE PARTY		A CHIMINING A MARKET		
(a) Applied to 1979, but not more th	THE RESIDENCE OF THE PARTY OF T			(-)	
(b) Applied to undistributed income					
(Election required)					
(c) Treated as distributions out of co					
required)		•			
(d) Applied to 1980 distributable arr	nount				(2-756-2
(e) Remaining amount distributed or		4541892			
5 Excess distributions carryover applied		-			
(If an amount appears in column	(d), the same				
amount must be shown in column (a					
6 Enter the net total of each column	n as indicated	9000			
below:				BANGGA SHI WATANA WALANGA SA	3V::::::::::::::::::::::::::::::::::::
(a) Corpus. Add lines 3(f), 4(c), and	4(e). Subtract				
line 5		11407213			3\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
(b) Prior years undistributed incom	ne. Line 2(b)				
minus line 4(b). This amount is	taxable—File				
Form 4720					
(c) Undistributed income for 1979. L					
line 4(a). This amount is taxat	ole-File Form			_	
4720					
(d) Undistributed income for 1980.	Line 1 minus				
lines 4(d) and 5. This amount	must be dis-				-
tributed in 1981				AAN (AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	
7 Amounts treated as distributions ou					
satisfy requirements imposed by se	ections 170(b)	1, -			
(1)(D) or 4942(g)(3) (see instruction	THE PARTY OF THE P				
8 Excess distributions carryover from	CONTRACTOR OF NO.	(*7.1-1			
plied on line 5 or line 7 (see instruction					
9 Excess distributions carryover to 19		17517112			
minus lines 7 and 8.)					
10 Analysis of line 9:	1419484				
(a) Excess from 1976					
(b) Excess from 1977	2207523	-			
(c) Excess from 1978	4703121	-			
(d) Excess from 1979	4645.92	-			
(e) Excess from 1980	4541892				

Pa	rt XII	(See instructions and Part		on 9)	4/1						
1 (0) If the	foundation has received a rulin	g or determ	nination let	ter that it is a	perati	ing founda-				
•		and the ruling is effective for						<u> </u>		-	
(p		box to indicate whether you	are an of	perating fo	undation des	cribed i	n section [494	(i)(3) or [3 494	2(J)(6) (see
	instru	ictions).								-	
			Yes ye				Three Years	1		- (e)	Total
2 (*		ted net income (from Part I,	(a) 190	0 (6	1979	(e)	1976	(d)	1977	-	
		25(c) for 1980. Enter cor-				1					
	W. M. M. W. C.	nding amount for prior				1				1	
	years					-				-	
~	969/	of line (a)		- 1		1				1	
1997	e	ying distributions from Part								-	-
(0)		e 4 for 1980 (enter corre-								1	
	- 10 m	ling amount for prior years) .				!			,	1	
· 14	4000	nts included in (c) not used				-				·	
	-	y for active conduct of ex-								1	
		activities									
(0)	400000000000000000000000000000000000000	ying distributions made di-									
		for active conduct of exempt		- 1						1	
	purpo	ses (line (c) minus line (d)) .	,								
3 Co	mplete	the alternative test in (a),	1990 Company of the C				WHOO TO THE A TO THE	panerson mass	nonello. Pro trace-posegones		ar storumpanananan n ecipi
(b)	, or (c)	on which the organization		- 1		1				1	
rei	ies:					1				1	
(0)	"Asse	ts" alternative test-enter:				1				1	
		alue of all assets			************	_					
		alue of assets qualifying un-				1				1	
	d	er section 4942(j)(3)(B)(i) .	*************			_				-	
(b)	S. Granning and the	wment" alternative test-		1		1				1	
		% of minimum investment		1		1				1	
		shown in Part VIII, line 6		1		1				1	
		80 (enter 3/3 of comparable				1				ŀ	
	And a second	nt for prior years)				-				-	-
(c)		ort" alternative test-enter:				1					
		otal support other than		- 1		1				1	
	100	ross investment income (in-		- 1		1				1	
		rest, dividends, rents, pay-		1		1				1	
		ents on securities loans		1		1		1		1	
		ection 512(a)(5)), or royal-		1		i				1	
		upport from general public	•			-				-	
		nd 5 or more exempt organi-				1				1	
		itions as provided in section				1				1	
		42(j)(3)(B)(iii)				1					
		argest amount of support				1	***************************************			_	
		om an exempt organization		!		1					
		ee instructions)									
	(4) G	ross investment income				1					

TEMENT NO.		-		·	-			YEAR	ENDE	<u> </u>	980	
TATEMENT REGARDING AMENDE	1.	Pen					l			l		
THE THE THE THE THE THE THE	-	7 570		· · ·	T	T	 	T		 	T	Т
						 	†		*********	†	-	T
THIS RETURN IS BEING AMENDED TO	44.	674	~.	4 .	<u> </u>	1	1	-		distribution on the	-	T
INVESTMENT TYPE INCOME FROM PA										1	-	T
COL B. TAR HAS MEVIOUSLY BEEN COMP						1	1			1	1	T
ON THIS AMOUNT THERE ARE NO OF						1	1			1	1	T
TO THE REWARD												T
			'				00		ż	2001		
Atvenue FROM FILMS + BOOKS			<	232	313	>	Pe	, ,	.~ +	12	C. /	6
				.000	-							Γ
												L
A Second												
CHANGE IN TAK . PO I PART II L.	WE	_										L.
RESUCE THE AY 2% A 132153		44	647	>						<u> </u>	-	L
												L
					<u> </u>	1						Ŀ
												L
						_						L
								ļ		<u> </u>		L
					 		<u> </u>	<u> </u>		<u> </u>		1
						1-		 	<u> </u>	_		╀
					 	—	 	├ ──		—		╀
					—	ـــ	<u> </u>	_		 	 	+
						┼	_			 		╀
				<u></u>	 	┼	 	 		├	+	╀
	-		-		├	┼	┼─	├			+	╀
					┼	┼		├.		┼	+	╀
	_				├	┼	-	-		┼	+	+-
					 	┼	-				+	╀
						┼─	 	 		 	+	╀
				<u> </u>	 	+	┼	 			+	╁
			-			+	 	 	-		+	┿
				<u> </u>		┼	┼	 	-	+	-	╁
	-			<u> </u>	┼	+	+	 	-	-	+	╀
						+	 		-	 	+	╁
	 	-	-		+	+-	 	 		+	+	+
	 	 			+	+	+		-	+	+	+
	 	 	 	 	+	+-	+	 	-	+	+	+
	 				+	+	1			+	+	+
	┼──	 	 		 	+	+	 	-	 	+	+
	 	 	 		-	+	 	 		+	+	+
	 	 	 	-	+	+	+	-	 	+	+	+
				- 10 M			-				T	